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ABSTRACT
Pharmacological Regulation of c-myc Gene Expression in Human Breast Cancer
Cells
Zaroui K. Melkoumian

Previous studies demonstrated that quinidine causes G1/G0 cell cycle arrest and
inhibition of proliferation in MCF-7 human breast cancer cell line (Woodfork, K. et al,
1995). The goal of studies reported here was to understand the molecular mechanisms of
c-myc gene regulation by quinidine. c-myc is one of the most common oncogene
aberrations in breast cancers (Deming, S.L. et al, 2000). c-myc functions include
regulation of cell cycle, proliferation, differentiation, and apoptosis. The results of these
studies demonstrated that quinidine causes rapid (within 1 hour) suppression of Myc
protein and mRNA levels that precedes the quinidine-induced G1 cell cycle arrest point
(D point) in MCF-7 cells. Additionally, the activity of c-myc promoter was suppressed by
quinidine over the same range of concentrations that suppress levels of c-myc mRNA and
protein, suggesting that changes in Myc protein and mRNA levels by quinidine may be
attributed to its effect on c-myc promoter. A 168 bp region of c-myc promoter (-100 to
+68 in respect to P1) was identified as a quinidine responsive region (QRR). Suppression
of Myc by quinidine was consistent with inhibition of growth and induction of more
differentiated phenotype in four different breast tumor cell lines. In contrast, quinidine
had minimal effect on Myc levels or proliferation in normal mammary epithelial cell
lines. Furthermore, MCF-7 cells treated with c-myc antisense oligonucleotides exhibited
cytoplasmic lipid droplets, similarly to the quinidine-treated cells, suggesting that
suppression of Myc may play a causative role in the induction of more differentiated
phenotype by quinidine in human breast cancer cells.
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I. INTRODUCTION
1. Breast Cancer
1.1. Current methods of breast cancer therapy
Worldwide, breast cancer remains the most common malignancy affecting women,
accounting for 18 % of all female cancers (McPherson, K. et al, 2000). In the United States
each year more than 180,000 women are diagnosed with breast cancer and 44,000 will die
from this disease (NIH, 2000) making it the second leading cause of cancer death among the
females after lung cancer. Risk factors for the development of breast cancer include older
age, immediate family history of breast cancer at a young age or bilateral breast cancer, early
menarche, late menopause, nulliparity, use of hormone replacement therapy, exposure to
ionizing radiation at a young age, lifestyle, and past history of atypical hyperplasia, in situ or
invasive carcinoma (McPherson, K., et al, 2000).
Current methods of breast cancer therapy include surgery, radiation, cytotoxic and
hormonal chemotherapy, and preventive chemotherapy. The clinical management of breast
cancer patients is guided by the number of parameters, including tumor size, histological type
or grade, the presence of steroid receptors, involvement of the axillary lymph nodes, and
presence of metastasis (NIH, 2000). Carcinoma in situ is a preinvasive lesion within breast
without penetration of the basement membrane and the potential for metastasis. Intralobular
and intraductal carcinomas in situ are treated with the local surgical excision and wide local
excision following by irradiation, respectively (Harris, J.R. et al, 1992). Primary breast
cancers are treated with modified radical mastectomy or partial mastectomy following by
external beam irradiation (Fisher, B. et al, 1989). Axillary lymph node dissection during the
surgery is necessary to determine the adjuvant therapy of choice, since axillary nodal
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involvement is predictive of relapse in operable breast cancer. Because adjuvant
polychemotherapy (≥ 2 agents) has been shown to substantially improve the long-term,
relapse-free, and overall survival, it should be recommended to the majority of women with
localized breast cancer regardless of nodal, menopausal, or hormone receptor status (NIH,
2000). The currently recommended adjuvant therapy includes tamoxifen treatment for five
years among women aged over 50 years and standard oral CMF (Cyclophosphamide,
Methotrexate, 5-Fluorouracil) for six months or ovarian ablation in women younger than 50
years (NIH, 2000; Fisher, B. et al, 1990; Wood, W.C. et al, 1994). The benefit from
tamoxifen therapy is nearly doubled for patients with Estrogen Receptor (ER) rich tumors
compared to ER poor ones.
Virtually all of the deaths in the United States due to breast cancer are associated with
progressive metastatic breast cancer. Unfortunately, there is no cure for this stage of breast
cancer, although the length and quality of patients’ lives with metastatic cancer varies
greatly. Clinical studies showed that about one third of patients with metastatic breast cancer
will respond to endocrine therapy (Glauber, J.G. and Kiang, D.T., 1992). Endocrine agents
are best used as initial therapy in older patients with ER-positive tumors. First-line endocrine
therapy for postmenopausal patients generally consists of tamoxifen, followed by a progestin
(Megestrol acetate), high dose estrogen, an aromatase inhibitor (Anastrozole), or androgen
(Fluoxymesterone)

when

tumor

progression

occurs.

For

premenopausal

patients,

oophorectomy or tamoxifen treatment may be considered first, followed by progestin or
androgen treatment in the event of progression (Glauber, J.G. and Kiang, D.T., 1992). The
median duration of response to any of these endocrine therapies is between one and two
years. Although chemohormonal treatment may lead to higher response rates compared to
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hormonal therapy alone, a survival benefit has not been demonstrated. About two-thirds of
all patients with metastatic breast cancer will have a response to some form of cytotoxic
chemotherapy. The median duration of response is six to twelve months (Henderson, I.C. and
Harris, J.R., 1991). The most widely used combinations in the treatment of metastatic breast
cancer

are

CAF

(Cyclophosphamide,

Adriamycin,

5-Fluorouracil)

and

CMF

(Cyclophosphamide, Methotrexate, 5-Fluorouracil) (Abramowicz, M., 2000). Second-line
therapy for refractory patients results in lower response rate and duration of response
compared to those for front-line therapy. Paclitaxel (Taxol) is recommended for second-line
therapy of metastatic breast cancer (Seidman, A.D., 1994). Other second-line agents include
mitomycin C and vinblastine, yielding response rates of 25 to 30% (Henderson, I.C. and
Harris, J.R., 1991).
The major limitation associated with the use of cytotoxic chemotherapeutic agents is their
lack of selectivity for tumor cells and associated with it toxicity in normal tissues. In general,
anticancer drugs affect rapidly dividing cells. These include tumor cells, hematopoetic cells,
cells that line the digestive tract, and hair follicle cells. Accordingly, the most common side
effects of cancer chemotherapy are immunosuppression, GI disturbances, and alopecia (hair
loss). There are also other toxicities associated with some anticancer drugs. For example,
high doses of methotrexate can cause acute renal failure and neurotoxicity. Doxorubicin at
cumulative doses exceeding 450 mg/m2 causes significant cardiotoxicity (Von Hoff D.D. et
al, 1979). Also mutagenic potential of some chemotherapeutic agents can cause development
of secondary tumors, such as leukemia. There are several side effects associated with
endocrine therapy as well. Recent study by Fisher, B. and coworkers (Fisher, B. et al, 1998)
showed that tamoxifen increases the women's risk for three rare but life-threatening health
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problems: endometrial cancer (cancer of the lining of the uterus), pulmonary embolism
(blood clot in the lung), and deep vein thrombosis (blood clots in major veins). Another
important problem in cancer therapy is a development of resistance to antineoplastic drugs.
Were it not for drug resistance, control and cure of most cancers would be possible.
Some of the most exciting developments in cancer research were the discovery of
oncogenes and tumor suppressor genes, as well as the better understanding of the internal and
external stimuli that result in malignant transformation, tumor progression, invasion, and
metastasis. The advances in our understanding of the basic biology of breast carcinoma
contributed to the development of novel approaches to cancer treatment to supplement
traditional chemotherapy. One such example is a development of monoclonal antibody,
trastuzumab (Herceptin) to epidermal growth factor receptor HER-2/neu. This antibody binds
with great affinity to the extracellular domain of HER-2 and inhibits the transmission of
growth stimulatory signal. In clinical trials Herceptin as a single agent has been shown to
produce antitumor responses in 15-20 % of patients with metastatic breast carcinoma
(Baselga, J. et al, 1998; Cobleigh, M.A. et al, 1998). Another area of intensive research is the
development of Selective Estrogen Receptor Modulators (SERM). Based on our growing
knowledge about estrogen receptor subtypes, their distribution and functions in different
tissues, researchers are searching for compounds, that would function as a potent antiestrogens in the breast and uterus to prevent estrogen-driven cell proliferation and, at the
same time, have strong estrogenic effects in bone, the cardiovascular system, and the central
nervous system, where the hormones have beneficial effects. To date, the only three SERM
available on the market are tamoxifen (Nolvadex), raloxifene (Evistar), and toremifene,
although there are more second and third generation SERM showing promising results in
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preclinical data (McNeil, C., 1998, Williams, G.M., 1998; Labrie, F. et al, 1999). Selective
targeting of deregulated oncogenes in cancer cells with antisense oligonucleotides or delivery
of disrupted tumor suppressor genes using viral vectors are other advancing areas in cancer
research.
Due to the tremendous progress in breast cancer research, for the first time the annual
mortality rates are decreasing in the United States (NIH, 2000). There is still more to learn
about breast cancer genetics, breast cancer susceptibility genes, such as BRCA1 and BRCA2,
molecular mechanisms regulating mitogenic stimulation, and malignant transformation in
breast cancer cells. This knowledge may reveal new pharmacological targets for the
development of better therapeutic approaches to treat breast cancer.
The next section of the introduction provides a general overview of basic cell cycle
regulatory processes, as well as more detailed discussion of G1 to S phase transition in MCF7 human breast cancer cell line. The purpose of these background materials is to facilitate
understanding of the subsequent sections of the introduction, disusing functional role of cmyc gene in cell cycle regulation.
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2. Cell Cycle
2.1. General overview
The cell cycle is a sequence of highly ordered and controlled processes that results in a
duplication of a cell. The cell cycle consists of 4 distinct phases: G1, S, G2 and M. DNA
replication and cell division (cytokinesis) occur during the S and M phases, respectively. Gap
phases (G1 and G2) precede S and M phases and are responsible for the synthesis of essential
proteins for DNA replication and mitosis. Certain conditions, for example starvation,
differentiation cause cells to exit from the cell cycle into a non-proliferative state, called G0
phase. Some non-dividing cells, such as skeletal muscle fibers, are unable to re-enter the cell
cycle. Other, such as lymphocytes, hepatocytes and fibroblasts are usually in G0 but can be
activated by external agents (mitogens) to enter cell cycle. Each phase of the cell cycle is
regulated by three families of key cell cycle regulatory proteins: cyclins, Cyclin Dependent
Kinases (CDKs), and Cyclin-dependent Kinase Inhibitors (CKIs). In response to mitogenic
stimuli, such as growth factors, there is a transient increase in levels of cell cycle phasespecific cyclins. Each cyclin binds to the corresponding CDK and activates its catalytic
subunit. Activated CDK then phosphorylates another important cell cycle regulator, the
retinoblastoma protein, pRb. A schematic diagram of the temporal relationship between
different cyclin/CDK complexes and cell cycle phases are shown in Figure 1. Cyclin D1 is
expressed throughout G1 phase but its peak occurs during mid G1. The main function of
cyclin D1 is to activate CDK4/6 catalytic subunits to induce initial phosphorylation of pRb.
Cyclins E and A begin to rise later in G1. They are responsible for activation of CDK2 to
maintain pRb in its hyperphosphorylated state during the late G1 and ensure G1 to S
progression. In its hypophosphorylated form pRb is bound to the family of heterodimeric
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Figure 1. Temporal relationship between expression of Cyclin-Cdk complexes (dashed
lines) and different phases of cell cycle (solid lines).
R – late G1 restriction site
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transcription regulators, collectively called the E2Fs, which can transactivate genes whose
products are essential for S phase entry. Some of these genes are dihydrofolate reductase,
thymidylate synthase, DNA polymerase α, and DNA polymerase δ subunit PCNA.
In the complex with pRb, E2Fs are unable to perform their function as transcription
factors. Phosphorylation of pRb by CDKs removes its inhibitory capacity, causing release of
E2Fs, which then transactivate the expression of genes needed for entry into S phase.
Activation of E2F-1 also leads to transcriptional activation of cyclin E and A, reinforcing the
initial activation of E2F. Figure 2 summarizes these events. Extracellular stimuli initiate
progression of cells from G1 to S; other events regulate progression of cells from S phase
into G2 and from G2 into M phase. These transitions are controlled by internal signals that
are triggered by the completion of biosynthetic processes unique to S and G2 phases,
respectively. They are insensitive to external conditions (Murray, A.W. and Kirschner,
M.W., 1989). The point in G1 phase beyond which a cell is no longer dependent on the
presence of extracellular factors and is committed to complete cell cycle is called the G1
"restriction point" or “R point" (Pardee, A.A, 1974). When fibroblasts are arrested in R, for
example by withdrawal of growth factors for a long period of time, they will enter quiescence
state or G0 (Campisi, J. and Pardee, A.B., 1984).
In addition to the positive regulation by cyclins, CDK activity is negatively regulated by
another important family of cell cycle regulatory proteins: Cyclin-dependent Kinase
Inhibitors, CKIs. These inhibitors can be up-regulated when required, thus blocking the
activation of CDKs by cyclins. The known CKIs are grouped into two gene families, Ink4
and Cip/Kip, according to structural similarities. The Cip/Kip family consists of p21, p27,
and p57. p21 is also known as Wild-type p53 Activated Fragment 1 (WAF1) or CDK2
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Interacting Protein 1 (CIP1). p27 and p57 are known as Kinase Inhibitory Protein 1 (Kip1)
and 2 (Kip2), respectively. These inhibitors tend to have wide ranging roles and can
potentially inhibit a number of different CDKs. The Ink4 (for inhibitor of CDK4) family is
far more specific and consists of p15 INK4b, p16

INK4a

, p18

INK4c

, p19

INK4d

(Anxo Vidal and

Andrew Koff, 2000). Until recently it was thought that Ink4 family members were only
involved in inhibiting CDK4. However, a second INK4A gene product has been identified
recently, p19

ARF

, which binds to and inactivates the p53 regulatory protein, MDM2, thus

allowing increased p53 stability and subsequent cell cycle arrest (Pomerantz, J. et al, 1998).
Abnormalities in many positive and negative modulators of the cell cycle are frequent in
most cancer types. As a result, cancer cells possess increased and deregulated proliferative
activity. In normal cells, cell cycle regulators are subject to strict control and their activities
fluctuate according to external stimuli (growth factors), whereas in tumor cells a variable
degree of independence from such stimuli seems to emerge.
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Figure 2. Schematic representation of pRb phosphorylation by cyclin/CDK complexes
and E2F release during G1 to S progression.

Members of the Ink and Cip/Kip families of cyclin-dependent kinase inhibitors (CKI) are
shown in blue and green, respectively.
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2.2. G1 to S phase progression in MCF-7 human breast cancer cells
The goal of these studies was to understand the molecular mechanisms of c-myc gene
regulation by quinidine in human breast cancer cells. A brief description of the cell cycle in
MCF-7 cells, with the emphasis on G1-S progression in this cell line is provided. Most of the
data described in this section were obtained in Dr. Strobl's and Dr. Wonderlin's laboratories.
A schematic diagram of G1 to S progression, the temporal relationship between two
different G1 control points, and the levels of cell cycle regulatory proteins in MCF-7 cells is
shown in Figure 3. The doubling time of MCF-7 cells was calculated by counting cell
numbers in a cell population engaged in exponential growth. The doubling time was 52
hours. The fraction of cells in G1, S , and G2+M phase was calculated using flow cytometry
analysis and immunohistochemical staining of Ki-67 antigen (Shiyi Wang, et al, 1998). Flow
cytometry allows one to calculate the percentage of cells in G1+G0, S, and G2+M phases,
based on their DNA content, but it does not discriminate between cells in G1 and G0 phase.
Ki-67 is the nuclear antigen, that is present only in cycling cells (G1, S, G2, and M phases)
and is absent in G0 cells, allowing for distinction of cells in G0. Based on the cell doubling
time and cell fraction in each cell cycle phase, the duration of G1, S, and G2+M was
estimated to be 32, 15 and 5 hours, respectively (Shiyi Wang, et al, 1998).
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Figure 3. Temporal relationship between different regulatory events during the G1 to S
phase transition in MCF-7 human breast cancer cells.
0he duration of the G1 and S phases is shown in black and red solid lines, respectively. The
time required for the cells to reach mid-S phase, after washout of lovastatin (21hr) or
quinidine (27 hr), or after release of cells from a high cell density condition (30 hr) is shown
with black brackets. The peak of Myc protein occurs 1.5 hr after release from the high
density state as shown by the arrow. The phosphorylation status of pRb is shown in black
(hypophosphorylation) and red (hyperphosphorylation), respectively. D-quinidine arrest
point, L - lovastatin arrest point, G0 - G0 state. Based upon data published in Woodfork,
K.A. et al, 1995; Strobl, J.S. et al, 1995; Wang, S. et al, 1998; Zhou, Q. et al, 2000; Wang, S.
thesis, 1996; Melkoumian, Z. and Strobl, J., 1999.
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Over the past several years, our laboratory has tried to define the mechanism, by which
the potassium channel blocking agent, quinidine, inhibits proliferation in human breast
cancer cells. Studies by Woodfork, K. showed that quinidine caused arrest of MCF-7 cells in
G1/G0 phase of the cell cycle (Woodfork, K.A. et al, 1995; Strobl, J.S. et al, 1995). This
quinidine arrest point was called the depolarization control point or D point. The important
role of membrane potential and its changes by quinidine in regulation of cell progression
through the D point are discussed later in the introduction. Shiyi Wang estimated the
location of the D point by comparing the time course of synchronous S phase re-entry after
drug washout form MCF-7 cells arrested in G1/G0 phase by quinidine or known G1 arresting
drug, lovastatin (Shiyi Wang et al, 1998). Cells arrested by lovastatin and quinidine peaked
in mid S phase 21 and 27 hours, respectively after the drug washout. Accordingly, the Dpoint was designated prior to the lovastatin arrest point and 19.5 hours preceding the G1/S
border. In general, MCF-7 cells growing in tissue culture reach the high density/confluency
state around 5-6 days after passaging. At this state the cell monolayer covers about 90% of
the growth surface and most of the cells are in G1/G0 (Wang, S., et al, 1998). The flow
cytometry analysis showed that MCF-7 cells released from the high density state peak in mid
S phase 30 hours later, suggesting that the high density state is located 22.5 hours away from
G1/S border. At this stage we cannot clearly define the entry location of G0 into G1 phase. If
most of the high density cells represent a G0 population, then the G0 to G1 entry point is
located 22.5 preceding the G1/S border. In our results, a transient spike of c-Myc protein
expression occurs after release of MCF-7 cells from the high density, with its peak at 90 min
(Melkoumian, Z. and Strobl, J., 1999), 1.5 hours prior to the D point. c-myc is an early
response gene, whose rapid induction is essential for the cells to progress from G0 to G1 and
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progress through early G1 phase of the cell cycle. Inhibition of c-myc using antisense
approaches causes arrest of MCF-7 cells in a G1/G0 state (Watson, P.H. et al, 1991). c-Myc
protein acts as a transcription factor to activate expression of so called delayed-response
genes, such as cyclin D1, CDK4, cdc25A, whose products are necessary for G1 to S
progression.
In our model, quinidine causes rapid suppression of c-myc gene expression, which
prevents progression of cells through the G1 phase, perhaps due to preclusion of Mycdependent events later in G1. Myc-dependent events may include the synthesis of delayedresponse genes, listed above, as well as others, whose presence is essential for progression of
the cells through the D point. As a result, we hypothesize, cells are arrested in the D point.
Washout of the quinidine would allow for Myc-dependent transcription to occur, and cell
progression through G1 to S phase. In fact, Shiyi Wang showed a significant increase in
cyclin D1 mRNA levels 12 hours after quinidine washout (Shiyi Wang, thesis, 1996).
Unfortunately, she did not examine the earlier time points, to establish how soon after
quinidine washout cyclin D1 mRNA levels begin to rise. In accordance with this increase in
cyclin D1 mRNA, Zhou, Q. showed an accumulation of hyperphosphorylated form of pRb 24
hours after the release of cells from high density, although he did not test pRb
phosphorylation status between 12 and 24 hours (Zhou, Q. et al, 2000). Collectively, these
data are consistent with a model, where an early induction of c-myc gene during G0 to G1
and early G1 progression allows for the synthesis of delayed cell cycle regulatory proteins,
that are essential for the progression through the D point. Inhibition of this c-myc induction
by quinidine prevents transcription of c-myc regulatory genes and consequently, cells become
arrested at the D point.
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3. c-myc Gene
3.1. c-myc is a protooncogene
A major contribution towards understanding the mechanisms of tumorigenesis has
been the discovery of protooncogenes and tumor suppressor genes. Protooncogenes or concogenes (cellular homologues of oncogenes) are genes that are normally involved in the
regulation of cell proliferation and can lead to the cancer when they are abnormally
expressed in the cell. A mutated, cancer-causing version of a protooncogene is called an
oncogene. Oncogenes were first isolated as part of small genomes of RNA tumor viruses,
called acute transforming retroviruses (Bishop, J.M., 1983). These viruses efficiently
transform cells in culture and in animals. It was then found that oncogenes carried by those
viruses were responsible for their transforming capabilities. Originally, oncogenes were
thought to be an innate part of the viral genome. Only later, when similar, but nonidentical,
copies of the oncogenes were found in normal vertebrate cells, did it become clear that viral
oncogenes arose as a consequence of genetic recombination between retroviruses and
protooncogenes (Bishop, J.M., 1983). Placement of those protooncogenes in the path of
strong viral promoters or their oncogene-converting mutation within the viral genome would
cause continuous, uncontrolled activation of their normal functions in infected cells. Since
most protooncogenes are involved in the regulation of some aspect of cell proliferation, their
uncontrolled expression would lead to cellular transformation. To date, more than 70
oncogenes have been identified. Tumor suppressor genes are genes that negatively regulate
cell proliferation and the loss of their function by mutation can contribute to the development
of cancer.
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The myc gene was originally identified as the oncogene v-myc (viral myc) of the
MC29 avian myelocytomatosis virus (AMV) (Sheiness, D. et al, 1978, Sheiness, D. and
Bishop, J., 1979). This retrovirus induces carcinomas, endotheliomas, sarcomas, and the
leukemic disorder myelocytomatosis (hence myc) in susceptible birds. They transform
fibroblasts and macrophages in tissue culture (Graf, T. and Beug, H., 1978). The c-myc gene
was first isolated as the chicken cellular homologue of v-myc (Vennstrom, B. et al, 1982).
Subsequently the human, mouse, and rat c-myc genes were cloned and characterized (DallaFavera, R. et al, 1982; Stanton, L. et al, 1984, Hayashi, K. et al, 1987). It was soon
recognized that activated, oncogenic c-myc is a key transforming agent in the etiology of
human Burkitt's lymphoma (Dalla-Favera, R. et al, 1982; Varmus, H.E., 1984). Altered cmyc expression has been also shown in a wide variety of human tumors including breast,
colon, and cervical carcinomas, small cell lung carcinomas, osteosarcomas, glioblastomas,
and myeloid leukemias (Marcu, K., et al, 1992; Spencer, C., et al, 1991). Soon after the
discovery of the c-myc gene, two other genes N-myc and L-myc were identified as amplified
myc-related genes in human neuroblastoma and small cell lung carcinoma, respectively. The
myc family of oncogenes currently consists of three well-characterized members: c-myc, Nmyc, L-myc and two additional genes, B-myc and S-myc, that have been identified only in
rodents. The c-, N-, and L-myc genes share similar genomic organization and the
corresponding proteins contain several regions of high sequence homology. The genomic
structures of both S- and B-myc have diverged significantly from the other members of the
family and their promoters are not well characterized at present.
c-Myc and cell transformation Regulated c-myc gene expression is critical for controlled
cell proliferation, whereas deregulated expression of c-myc is a characteristic of tumor-
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derived cells. Genetic alterations leading to oncogenic activation of c-myc include gene
amplification (Favera, D. et al, 1982), chromosomal translocation (Magrath, I., 1990),
proviral insertion (Payne, G. et al, 1982), and retroviral transduction (Fulton, R. et al, 1987).
Also, changes in Myc protein levels by point mutation in c-myc coding sequence have been
reported in several tumors (Bhatia, K et al, 1993). Alterations in c-myc expression have been
demonstrated in many types of cancer, including Burkitt’s lymphoma, myeloid and plasma
cell leukemia, breast carcinoma, cervical carcinoma, small cell lung carcinoma, colon
carcinoma, osteosarcoma, and glioblastoma (Cole, M.D. et al, 1986; Spencer, C. and
Groudine, M., 1991; DePinho, R. et al, 1991). More direct evidence for the role of c-myc in
abnormal cell growth comes from studies of transformed cells and transgenic animal models.
Myc is capable of transforming fibroblast cell lines in vitro (Small, M. et al, 1987; Stone, J.
et al, 1987) and established cells expressing activated c-myc form tumors in animals (Keath,
E.J., et al, 1984).

Transgenic animal models have demonstrated convincingly that

deregulated expression of Myc induces tumorigenesis (Henriksson, M. and Luscher, B.,
1996). Two groups created transgenic mouse strains harboring c-myc genes linked to either
the mouse mammary tumor virus (MMTV) long terminal repeat (Stewart, T.A. et al, 1984) or
the immunoglobulin heavy-chain enhancer (Adams, J.M. et al, 1985). In the first group, the
mice developed mammary adenocarcinomas at high frequency, but only during the second or
third pregnancy. In the second group, virtually all animals developed B-cell lymphomas at
six-to-eight weeks of age, apparently due to the tissues-specific expression of the oncogene.
These data suggest an important role of c-myc in tumorigenesis. However, the mechanisms
by which c-Myc cause transformation remains unknown, although it has been shown that cMyc transactivates promoters of several growth promoting genes.
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The goal of these studies was to understand the molecular mechanisms of c-myc gene
regulation by quinidine in human breast cancer cells. The following sections of the
introduction focus on a review of structure, functions, and regulation of the c-myc gene.

3.2. c-myc gene organization
The human c-myc gene has been mapped to the 8q24 locus of the chromosome 8
(Taub, R. et al, 1982). It consists of three exons: an untranslated first exon (exon I) and two
protein coding exons (exons II and III). A schematic diagram of the c-myc gene organization
is shown in Figure 4. The c-myc gene has 2 major promoters P1 and P2 located 161
nucleotides apart in exon I. Transcription initiated at P1 and P2 produces 2.4 and 2.2 kb cmyc transcripts, respectively. These transcripts account for 95% of total c-myc mRNA. Two
other promoters: P0, located 500 bp upstream of P1 and P3, located in the intron I give rise to
less then 5% of c-myc mRNA each. Both P1 and P2 contain a consensus TATA box element.
A strong consensus initiator element (Inr) occurs only at the P2 transcription start site. A
number of different regulatory sequences have been described in the 5' upstream promoter
region, in the 5' and 3' untranslated regions, and within intron I. Regulation of c-myc
expression is highly responsive to environmental signals. Some of these regulatory domains
are shown in Figure 4 and their role in c-myc gene regulation will be discussed in the later
section of the introduction.
There is only one open reading frame (ORF) in all c-myc mRNA species. It starts at
the canonical AUG initiation codon located at the 5' end of exon II and codes for the major
64 kDa Myc protein observed in vivo (Hann, S. and Eisenman, R. 1984; Ramsay, G. et al,
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Figure 4. c-myc gene organization.
Exons 1,2, and 3 are represented by open rectangles. Shaded region shows the untranslated
portion of the exon 1. Transcription start sites, P0, P1, P2, and P3 are shown by arrows. A
more detailed diagram of the P1 and P2 promoter regions is shown in the lower portion of the
figure. Positions of several regulatory regions in respect to the start site for P1 promoter are
shown in black rectangles. CUG, AUG- translation initiation sites, polyA1 and 2polyadenylation sites, TATA = TATA boxes, TCE = TGFβ1 control element, Sp1 and E2F =
Sp1 and E2F binding sites, ½ ERE = half site of canonical estrogen responsive element, CTbox = CT-rich element, MBP-1 = binding site for the c-myc promoter binding protein-1, ERR
= estrogen responsive region, Inr = initiator element.
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1984). A minor protein species of 67 kDa is also observed. The translation of 67 kDa Myc
protein begins at a cryptic start codon CUG located at the 3' end of exon I in frame with the
previous ORF. The major translation product, p64, consists of 439 amino acids, p67 contains
an additional 14 amino acids at the N-terminus of the p64 sequence (Hann, S. et al, 1988).
Both products of c-myc gene (p64 and p67) are highly conserved nuclear phosphoproteins
with a half-life of about 20-30 min (Luscher, B and Eisenman, R., 1990). The relative
abundance of p67 versus p64, also known as Myc 1 and Myc 2, varies among tissues and cell
lines, with the p64 species being the major isoform in most cases. A third isoform of c-Myc
protein, termed Myc-S (short), has been described recently (Spotts, G.D.1997). This protein
originates from the translation initiation site approximately 100 amino acids downstream of
the N-terminus and lacks Myc transcription activation activity.

3.3. c-Myc protein structure
Both Myc proteins (p64 and p67) contain several structural domains characteristic of
the transcription factors. The first 143 amino acids of the amino terminus comprise the
transactivation domain (TAD) that contains two highly conserved Myc boxes (Mb): Mb I
(amino acids 45 to 63) and Mb II (amino acids 129 to 141). The later is essential for all
known Myc biological activities and is conserved among all Myc family members. Myc also
contains two nuclear localization sequences (NLS): a primary motif at amino acids 320- 328
and a secondary signal from 364-374. The C-terminus of Myc contains three important
domains: 1) the basic region (BR) (amino acids 355-368) implicated in specific DNA
sequence recognition and binding, 2) the helix-loop-helix (HLH) (amino acids 368-410) and
3) the leucine zipper (LZ) (amino acids 411-439) responsible for specific heterodimer
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formation between Myc and its binding partner Max (c-myc associated protein x).
Contiguous BR-HLH-LZ motifs are characteristic of transcription factors that bind to
specific DNA sequences.
Myc proteins can be phosphorylated at multiple sites by casein kinase II (CKII),
mitogen activated protein kinase (MAPK), p34cdc2 kinase, and glycogen synthase kinase 3
(Alvarez, E. et al., 1991; Henriksson, M et al, 1993; Pulverer, B. et al, 1994; Seth, A. et al,
1992). Of these sites, Thr 58 and Ser 62 appear to be the most functionally relevant, although
there are conflicting data published about the role of Thr 58/Ser62 phosphorylation in Myc
transcriptional activity. More investigations are required to clarify the importance of
phosphorylation in regulation of Myc functions.

3.4. Myc functions: Regulation of the cell cycle, cellular differentiation, and apoptosis
As has been discussed earlier, c-myc gene product belongs to the family of transcription
factors that bind as dimers to the specific DNA sequences on the target genes. Our
understanding of molecular functions of c-Myc has significantly advanced with the discovery
of the c-Myc dimerization partner Max. Max was originally identified by screening a human
cDNA expression library with a radiolabeled fusion protein containing the c-Myc carboxy
terminus (Blackwood, E. and Eisenman, R., 1991). Similarly to c-Myc, Max contains
contiguous BR-HLH-LZ motifs, and can form heterodimers with c-Myc, N-Myc, L-Myc,
members of MAD family of proteins, as well as homodimers with itself. All these complexes
bind to the same E-box sequences, CACGTG and CACATG, as well as to several lowaffinity, noncanonical DNA sequences (Prendergast, G.C. et al., 1991; Blackwell, T.K. et al,
1990; Blackwell, T. K., et al, 1993). Binding of Myc-Max heterodimers to the E-box
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sequences causes transactivation of Myc target genes in most cases, whereas Max-Max or
Max-Mad dimers, lacking transactivating function, may block the biological effects of MycMax dimers by competitive occupancy of the binding sites.
c-Myc and cell cycle. In general, c-myc expression is correlated with the proliferative
potential of the cell. Cells constitutively expressing high levels of c-Myc have reduced
growth factor requirements (Daczmarek, L. et al, 1985; Sorrentino, V. et al, 1986; Stern, D.
et al, 1986), spend less time in G1 phase (Karn, J. et al, 1989), and cannot become quiescent
(Kohl, N. and Ruley, H. 1987). In quiescent cells, c-myc expression is almost undetectable.
Upon mitogenic stimulation there is a rapid and transient burst in both c-myc mRNA and cMyc protein expression as cells enter the G1 phase, followed by a gradual decline to low but
detectable steady-state levels in proliferating cells (Campisi, J. et al, 1984; Kelly, K. et al,
1983; Moore, J. et al, 1987). Since this rapid induction of c-myc transcription occurs
independently of de novo protein synthesis, it was suggested that c-myc is an immediate
response gene, such as c-fos and c-jun, directly downstream of mitogenic signaling cascades.
A number of studies demonstrated that sharp induction of c-myc expression following serum
stimulation of quiescent cells is a prerequisite for normal transition from G0 to G1 and G1 to
S phase in nontransformed cells (Eilers, M. et al, 1989; Heikkila, R. et al, 1987; Shichiri, M.
et al, 1993). Whereas c-Myc plays a key role during the G0/G1 to S phase transition,
continuous low-level c-myc expression throughout the cell cycle suggests its importance in
other phases. Withdrawal of growth factors or treatment with differentiation-inducing agents
causes c-myc mRNA and protein expression to decrease to almost undetectable levels. In
contrast to c-Myc, expression of its partner, Max, is expressed at a constant low levels
throughout the cell cycle. Max has a half-life of 24 hours (Blackwood, E., Lucher, B., 1992),
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which implies that changes in Myc levels during the cell cycle play an important role in the
regulation of Myc-Max heterodimers. A schematic diagram of the expression levels of cMyc, Max, and Mad family of proteins during the cell cycle is shown in Figure 5.
c-Myc and cell differentiation c-Myc also plays an important role in cellular
differentiation. It has been shown in many cells that down-regulation of c-Myc expression
accompanies terminal differentiation and permanent withdrawal from the cell cycle.
Blocking c-Myc activity using antisense oligonucleotides, ectopic expression of Max, or
expression of dominant negative c-myc gene can induce differentiation of HL-60
(promyelocytic leukemia), F9 (teratocarcinoma), K562, and MEL (murine erythroleukemia)
cells (Canelles, M. et al, 1997; Griep, A and Westphal, H., 1988; Holt, J. e al, 1988;
Prochownik, E. et al, 1988). Conversely, independent studies showed that ecotpic c-Myc
expression from a transfected gene is sufficient to block the induction of differentiation in
MEL, 3T3-L1 preadipocyte, F9, PC12 neuronal, and U-937 monoblastic cell lines (Coppola,
J.A., and Cole, M.D., 1986; Dmitrovsky, E. et al, 1986; Freytag, S., 1988; Larsson, L., et al,
1988; Maruyama, K. et al, 1987, Onclercq, R. et al, 1989; Prochownik, E. and Kukowska, J.,
1986). These data suggest that suppression of c-Myc may be necessary for differentiation of
certain cell types, perhaps because withdrawal from the cell cycle by c-Myc down-regulation
is essential for terminal differentiation.
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Figure 5. Expression pattern of Myc family proteins in cycling and differentiated cells.
Expression levels of proteins are shown in solid lines of different colors. Myc/Max dimers
bind to the E-box sequence and transactivate Myc-target genes. Max/Max, Max/Mad,
Max/Mxi1 dimers bind to the same E-box sequence, but due to the lack of transactivation
domain, block the biological effects of Myc/Max dimers by competitive occupancy of their
binding sites.
Henriksson, M. and Luscher, B., 1996.
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c-Myc and apoptosis. A most paradoxical discovery from the work on c-myc was the
finding that under certain circumstances c-Myc is able to induce apoptosis or programmed
cell death. Separate studies in fibroblasts (Evan, G.I. et al, 1992) and in haemopoietic cells
(Askew, D.S. et al, 1991), revealed that constitutive expression of the Myc required the
presence of growth/survival factors in order for cells to proliferate. Withdrawal of serum
from fibroblasts or removal of interleukin 3 from haemopoietic cells expression Myc caused
cells to undergo apoptosis. The mechanisms of Myc-induced apoptosis are poorly
understood. Several genes involved in the regulation of apoptosis, such as p53, Bax, and p21
contain c-Myc responsive regions in their promoters, but the role of these genes in Mycinduced apoptosis remains unclear. The pro-apoptotic function of c-Myc resembles that of
several other oncogenes, such as E2F and E1A and might represent a safeguard mechanism
important during organism development. For example, increased levels of c-Myc during
development would allow for the proliferation of only those cells that receive the appropriate
survival signals. Otherwise, a Myc over-expressing cell, representing a potential danger to
the organism, would be eliminated by apoptosis. It has been hypothesized that c-myc
activation may facilitate tumorigenesis in cells in which a survival pathway was already
activated by mutation.
In summary, these data suggest a critical role of c-myc gene in the regulation of the
cell cycle progression, cellular differentiation and apoptosis. Deregulated expression of cmyc in a variety of tumors, the ability of exogenously expressed c-myc to transform
established cell lines in vitro and induce tumors formation in transgenic animals indicate an
important role of c-myc gene in tumorigenesis. Although the molecular mechanisms leading
to deregulated expression of c-myc gene in tumors are well understood, the precise cellular
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function of the c-Myc protein has remained an enigma, despite continuous efforts for more
then a decade to identify these functions. Some insight on these functions has been brought
with the identification of c-myc target genes, which are discussed in the following section.

3.5. Myc target genes
The role of Myc protein as a transcription factor was proposed long before any of its
target genes were identified, on the basis of certain structural features of the Myc protein.
The contiguous BR-HLH-LZ motifs in Myc are characteristic of a large class of transcription
factors, including AP4, the upstream stimulatory factor (USF) and the immunoglobulinenhancer, µE3-binding proteins (Johnson, P. and McKnight, S., 1989; Beckmann, H. et al,
1990; Carr, C. and Sharp, P., 1990; Gregor, P. et al, 1990).
The following criteria have been used to identify Myc target genes:
1. Presence of functional Myc-Max binding sites within the putative target gene.
2. Pattern of gene expression correlates with that of the Myc during transition from
quiescence to proliferation and/or differentiation.
3. Modulation of candidate gene's mRNA levels upon induction of Myc, or activation of
conditional Myc-ER fusion protein. In the latter case, the changes in mRNA should be
independent of de novo protein synthesis.
4. Functional role of the candidate target gene in c-Myc-mediated cell transformation and/or
proliferation.
5. Identification of DNA sequences physically associated with c-Myc in chromatin
preparations.
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A partial list of Myc target genes is shown in the Table 1. Products of some of these
genes function as key cell cycle regulatory proteins (cyclin D1, cyclin A, CDK4, p15Ink4b,
p21WAF1, cdc25A phosphatase, gadd 45). Others are involved in the regulation of cell
growth and metabolism (DHFR, LDH-A, CAD, ODC), transcription process (E2F2, eIF-2α,
eIF-4E), or apoptosis (p19 ARF, p53, p21WAF1). The data on cyclin D1 is very
controversial, with some reports showing up-, others down-regulation of cyclin D1
expression by c-Myc (Daksis, J.I. et al, 1994; Philipp, A. et al, 1994). Myc can also
negatively regulate its own expression (autoregulation) via the Initiator element located
within P2 promoter. In general, transcriptional activation of Myc-target genes by Myc-Max
heterodimers occurs via the E-box elements, whereas the Initiator element is responsible for
Myc-induced transcriptional repression. Both mechanisms are important for Myc-mediated
cellular transformation (Dang, C.V. et al, 1999).
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Table 1. c-Myc target genes

Gene

Myc
effect

Technique

Cellular function

CAD

Up

E-box (5'untranslated)

Pyrimidine biosynthesis

p19 ARF

Up

Guess

Apoptosis

p15Ink4b

Down

Initiator (P2 promoter)

Cell cycle regulation

p21WAF1/CIP1

Down

Promoter

Cell cycle regulation

cdc25A

Up

Guess/E-box (intron II)

Cell cycle regulation

Cyclin A

Up

Guess

Cell cycle regulation

Cyclin D1

Up/
Down

E-box (promoter)/differ and
Initiator

Cell cycle regulation

CDK4

Up

E-box (promoter)

Cell cycle regulation

DHFR

Up

E-box (promoter)

Growth and metabolism

E2F2

Up

E-box (promoter)

Transcription factor

eIF-2α

Up

Guess

Transcription initiation factor

eIF-4E

Up

Guess/ E-box (promoter)

Transcription initiation factor

p53

Up

Differ/E-box (exon I)

Tumor suppressor gene

Telomerase/
hTERT

Up

Guess/E-box (promoter)

Immortality

gadd 45

Down

Differ

Cell cycle regulation

Thrombospondin-1 Down

E-box (promoter)

Cell adhesion/metastasis

LDH-A

E-box (promoter)

Metabolic enzyme

Up
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ODC

Up

E-box (intron I)

Polyamine biosynthesis

c-myc

Down

Initiator (P2 promoter)

Transcription factor

Techniques used to identify putative c-Myc genes:
Guess - expression of target gene correlates with c-myc expression during transition from
quiescence to proliferation and/or differentiation. Functional importance for Mycmediated phenotypes.
Differ - differentially expressed genes upon enforced expression of c-Myc in the absence
of de novo protein synthesis.
E-box - presence of functional Myc/Max binding sites in the promoter or other region of
the candidate gene.
Initiator - presence of functional initiator element in the promoter of the candidate gene.
Up and Down indicate effect of c-Myc on the expression levels of the gene. CADcarbamoyl phosphate synthase, ODC - ornithine decarboxylase, LDH- lactate
dehydrogenase, DGFR - dihydrofolate reductase, eIF-4E and eIF-2α - eukaryotic
initiation factors.
Reviewed by Dang, C.V. et al, 1999; Galaktionov, K. et al, 1996; Philipp, A. et al, 1994;
Jones, R.M. et al, 1996; Reisman, D. et al, 1993; Shim, H. et al, 1997; Belo-Fernandez,
C. et al, 1993; Facchini, L.M. et al, 1997; Jansen-Durr et al, 1993; Daksis et al, 1994;
Hermeking, H. et al, 2000; Gartel, A.L. et al, 2001; Staller, P. et al, 2001.
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3.6. Role of c-Myc in breast tumorigenesis
c-Myc is one of the most common oncogene aberrations in breast cancer (Spaventi,
R. et al, 1993; Berns, E. et al, 1992; Garcia, I. et al, 1989; Escot, C. et al, 1986). According to
one study, c-myc amplification is a better prognostic marker than is c-erbB-2 (Berns, E. et al,
1992). In human breast cancers, c-myc is amplified in approximately 16%, rearranged in
approximately 5%, and over-expressed in the absence of gross locus alteration in nearly 70 %
of all cases, suggesting its importance in the genesis and/or progression of breast cancer
(Nass, S.J. and Dickson, R.B, 1997; Deming, S.L. et al, 1999).

3.6.1. Experimental evidence for the role of c-myc in breast tumorigenesis in breast cell lines
models
Constitutive expression of c-myc has been shown to partially transform both mouse
and human mammary epithelial cells (MECs), such that they grow in soft agar (anchorageindependent growth) in response to epidermal growth factor (EGF) and transforming growth
factor α (TGFα), and are no longer as dependent upon these growth factors for anchoragedependent growth as are the parental, non-transformed cells (Telang, N.T. et al, 1990;
Valverius, E.M. et al, 1990). Manipulation of the expression of c-myc gene in cell lines has
confirmed that c-myc is critical for the growth of breast cancer cells (Watson, P.H. et al,
1991). In estrogen receptor positive, hormone-dependent breast cancer cells (MCF-7 and
T47D), c-myc gene is directly regulated by estrogen (Dubik, D. and Shiu. R.P, 1988; Dubik,
D. and Shiu, R.P., 1992). In vitro nuclear run-on transcription assays demonstrated estradiolstimulation of c-myc gene transcription in MCF-7 cells, increasing c-myc mRNA
transcription more than 10-fold within 20 min. Estradiol had no effect on the c-myc mRNA
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half-life of about 20 min (Dubik, D. and Shiu, R.P., et al, 1988). Northern blot analysis
showed a similar pattern. The maximum c-myc mRNA accumulation of 12-fold, was
achieved one hour after addition of estradiol to MCF-7 cells. In a search for the mechanism
of estrogen-mediated activation of c-myc, a 116-bp estrogen responsive region (ERR) was
identified within the c-myc promoter (Dubik, D. and Shiu, R.P., 1992). This region contains
half-site of consensus ERE as well as Sp1 transcription factor binding site (GC-rich element)
(Figure 4). The presence of the GC-rich element may be important to estrogen-mediated
regulation of the c-myc promoter, since activation of several estrogen-responsive genes by
Sp1/ER complex as that bind to GC-rich element has been reported (Duan, R. et al, 1998;
Sun, G. et al, 1998; Qin, C. et al, 1999). In ER-negative MDA-MB-231 human breast cancer
cell line, c-myc is expressed at high constitutive levels and its expression is independent of
estrogens (Dubik, D. et al, 1987). Antisense c-myc oligonucleotides inhibit both estrogendependent and estrogen-independent growth of MCF-7 and MDA-231 cells lines,
respectively (Watson, P.H. et al, 1991). These studies in human breast cancer cell lines
indicate that Myc is important for cell growth (Shiu, R.P. et al, 1993).

3.6.2. Experimental evidence for the role of c-myc in breast tumorigenesis in transgenic
animal models
Three groups have independently developed transgenic mice that express the c-myc
oncogene in a mammary associated (mouse mammary tumor virus, MMTV-c-myc) or
mammary specific (whey acid protein gene promoter, WAP-c-myc) context (Stewart, T. et al,
1984; Schoenenberger, C. et al, 1988; Sandgren, E et al, 1995). WAP-c-myc transgenic mice,
developed by both groups demonstrated a high incidence of mammary tumors:
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adenocarcinomas in case of Schoenenberger's group or solid carcinomas in case of
Sandgren's group. In the both laboratories, tumor incidence approached 100% in multiparous
animals. In contrast, all virgin animals remained tumor-free over the fourteen months
observation period. These findings are as expected, on the basis of the temporal window for
the hormone-driven activity of the whey acid protein (WAP) gene promoter. The group,
which developed MMTV-c-myc transgenic mice reported 100% incidence of mammary
adenocarcinomas in multiparous animals (Stewart et al, 1984). Interestingly, WAP-c-myc and
MMTV-c-myc transgenic mice displayed a lengthy tumor latency, and strong dependency
upon pregnancy for tumor development. These data suggest that c-myc contributes, but in not
sufficient to induce mammary tumorigenesis. Two bitransgenic mice models: MMTV-cmyc/MMTV-v-Ha-ras developed by Sinn's group (Sinn, E. et al, 1987) and MMTV-cmyc/MT-tgfα developed by Dickson's group (Amundadottir, L. et al, 1995; Sandgren, E. et
al, 1995) demonstrated that deregulated c-myc expression synergized with deregulated v-Haras or tgfα expression to both accelerate mammary tumorigenesis and abrogate the
requirement for pregnancy in this process. Bitransgenic animals from the second group
showed the complete absence of normal mammary tissue and the ability of bitransgenic
mammary tissue from three-week-old mice to form tumors in athymic mice. These results
suggest that c-myc and tgf α, two important mammary gland relevant genes, are capable of
synergistically transforming the mammary epithelium, apparently requiring minimal, if any,
additional genetic alterations (Amundadottir, L. et al, 1995 and 1996).
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3.7. Regulation of c-myc gene expression
Expression of the c-myc gene is controlled by transcriptional initiation, transcriptional
elongation and posttranscriptional processes.

3.7.1. Regulation of transcriptional initiation
c-Myc is transcribed from multiple, independently regulated transcription initiation
sites. Two major promoters, P1 and P2, positioned 161 bp apart, give rise to 75-90% of cmyc mRNA. Two minor promoters, P0 and P3, lacking canonical TATA boxes give rise to
less than 5% of c-myc mRNA each.
Studies of c-myc chromatin have revealed multiple DNase I hypersensitive sites
(DH), some of which overlap with cis-acting c-myc regulatory elements. DNase I
hypersensitive sites mark perturbations in the regular chromatin structure that are usually
caused by the binding of regulatory proteins to DNA. The locations of DH sites, relative to
P1 promoter and their putative roles in c-myc regulation are listed in the Table 2 (Spencer, C.
and Groudine, M., 1991; Siebenlist, U. et al, 1984).
The DNA cis-acting elements are nucleotide sequences, usually located upstream of
the gene coding region, which are recognized and bound by specific regulatory transcription
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Table 2. Locations of DNase I hypersensitive (DH) sites in the c-myc promoter

DH site

Location

Putative role

DH I

-1851

negative repressor binding site

DH II1

-1380

unknown function

DH II2

-751

unknown function

DH III1

-124

associated with P1 promoter activity

DH III2

+91

associated with P2 promoter activity

DH IV

+800

correlates with the appearance of the block
of transcriptional elongation in differentiated
HL60 cells

DH V

+1800

unknown function

Locations are given in respect to P1 promoter.
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factors (trans-acting proteins), thereby causing the gene to respond to various regulatory
agents. A large body of work has been done to identify cis-acting elements of the c-myc
promoter that are involved in regulation of transcriptional initiation. Most of what we know
about c-myc regulatory elements has been identified by assaying the effects of promoter
sequence deletions on promoter activity within transfected cells. In this deletion/transfection
assay a series of c-myc deletion mutants linked to reporter genes, e.g. luciferase or
chloramphenicol acetyl transferase (CAT), were transiently transfected into mouse or human
cell lines and the relative promoter activities in different mutant constructs were analyzed.
The nature of protein-DNA interactions in a putative responsive region were assayed by
electrophoretic mobility shift assay (EMSA). Some of cis-acting elements identified within cmyc promoter employing the described methods are listed in the Table 3. The locations of the
elements are given relative to the P1 promoter.

3.7.2. Regulation of transcriptional elongation
Regulation of gene expression at the level of transcriptional elongation occurs in both
prokaryotic and eukaryotic systems. Transcriptional elongation mechanism plays an
important role in regulation of a number of protooncogenes, including c-myc, L-myc, c-myb,
c-fos, and c-mos. The region necessary for transcriptional blockage within c-myc has been
defined by a number of studies using the in vitro run-on assay. Bentley and Groudine were
the first to describe the c-myc transcriptional block phenomenon with their work on the
human c-myc gene (Bentley, D. and Groudine, M., 1986). A 95 bp sequence ending 35 bp 5'
of the exon1/intron1 boundary of the human c-myc gene was sufficient to effect premature
transcriptional termination in Xenopus oocytes when cloned downstream of the HSV tk
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promoter (Bentley, D and Groudine, M., 1988). In wild-type c-myc templates, transcripts
terminate prematurely at two thymine-rich sequences: a T7 stretch 20 bp upstream and a
T4/T7 stretch 30 bp downstream of the exon I/intron I boundary, respectively. c-Myc
transcription has been shown to be extremely pliable to various growth factors, mitogens and
differentiation agents that may act by altering elongation. For example, a rapid and dramatic
increase in c-myc transcriptional blockade was observed upon exposure of HL60 cells to
retinoic acid (RA) (Asselin, C. et al, 1989), DMSO (Eick, D. and Bornkamm, G., 1986), or
vitamin D (Simpson, R. et al, 1987). The intensity of DH IV site within intron 1 was shown
to increase with block of transcriptional elongation. The 10-fold increase in the block of
transcriptional elongation in HL60 cells treated with DMSO occurred within 30 min of
treatment (Eick, D. and Bornkamm, G., 1986). Between 24 and 48 hours after treatment, the
level of transcriptional initiation in exon I also declined. These experiments suggest that the
block of transcriptional elongation can control c-myc mRNA levels during cellular
differentiation. Also, an increase in c-myc steady-state mRNA, partially due to a release of
the elongation block, occurs in quiescent normal peripheral blood T lymphocytes stimulated
by phorbol myristate acetate (PMA) (Lindsten, T. et al, 1988).
In summary, these data suggest that regulation of c-myc transcription can be also
achieved at the levels of transcriptional elongation in addition to initiation. It is possible that
the abnormal regulation of c-myc expression that occurs in tumors may, in some cases, result
from disruption of the block of transcriptional elongation process.
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Table 3. Cis-acting elements or regions identified within c-myc gene promoter
Cis-acting element

region from -60 to -37

five tandem CT-boxes
(CCCTCCCC) located 101
bp upstream P1

Description
Essential for P1 transcription (Nishikura, K., 1986). It
contains a GC-rich sequence CCGCCC (-38 to -43) that
binds Sp1 and Sp3 transcription factors (Majello, B. et al,
1995). Sp1 and Sp3 proteins belong to a multigene family
whose members have similar, if not identical DNA binding
activities (Hagen, G. et al, 1992). Both Sp1 and Sp3 bind to
GC-rich and CT-rich boxes with comparable affinities
(Majello, B. et al, 1995). In vivo transfection experiments
have shown that Sp1-mediated transactivation of Sp1responsive promoters are repressed by Sp3.
Required to promote transcription from P1 and for maximal
activity of P2 (DesJardins, E. and Hay, N., 1993). Mutations
of these CT-boxes decreases the absolute and relative
activities of P1 and P2 promoters. CT-boxes were shown to
bind Sp1/Sp3 (DesJardins, E. and Hay, N., 1993) as well as
ZF87/MAZ transcription factors.

a single copy of the CT-box This element has an inhibitory effect on P1 and is required
for P2 transcription, respectively. It can bind both Sp1/Sp3
(CCTCCCTCCCT) in an
and MAZ transcription factors (DesJardins, E. and Hay, N.,
inverted orientation located 1993).
53 bp upstream P2
two E2F binding sites,
GATCGCGC (+122 to
+129) and GCGGGAAA
(+99 to +106)

Cooperate with Sp1 in transactivating c-myc P2 promoter
(DesJardins, E. and Hay, N., 1993; Majello, B. et al, 1995).

a 116 bp estrogen
responsive region (ERR)
located between +25 and
+142

Important for estradiol-induced activation of c-myc
promoter in MCF-7 and HeLa cells (Dubik, D. and Shiu, R.,
1992). This region contains half site of consensus estrogen
responsive element (ERE) (+76 to +80) as well as Sp1/E2F
(+98 to +106) binding sites, which can cooperate in
transactivating estrogen-responsive promoters (Duan, R. et
al, 1998; Sun, G. et al, 1998; Qin, C. et al, 1999).
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transforming growth factor
β1 (tgf β1) control element
(TCE) located upstream P1
between -63 and -83

Inhibits c-myc P1 transcription initiation, possibly via the
pRb gene product (Pietenpol, J. et al, 1991).

26 bp region (-343 to - 318)

Negative regulatory element. Containing binding site for
Ap1 transcription factor (Takimoto, M. et al, 1989).

CGCTGAGTA region from
+127 to +135, just
5'upstream of the P2 TATA
box

Binds MBP-1 (myc promoter binding protein 1), and
appears to be a negative regulator of c-myc transcription
(Ray, R. and Miller, D., 1991).

The locations of the elements are given in respect to P1 promoter unless otherwise specified.
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4. Role of c-myc in TGF-β
β Signaling
Transforming growth factor β (TGF-β) is a prototypic member of a large family of
cytokines that plays an important role in a variety of biological processes, including cell
division, differentiation, adhesion, movement, and death (Derynck, R. and Feng, X., 1997).
TGF-β has a strong growth inhibitory effect on epithelial and other cell types. It is not
surprising, that TGF-β signaling is lost in some cancers by inactivation of TGF-β signal
transduction components (Massague, J. et al, 2000). There are three families of TGF-β
receptors, type I (RI), II (RII), and type III (RIII) receptors. The RI and RII are
transmembrane serine/threonine kinases with a single transmembrane domain. Free receptors
exist in cell membrane as homodimers. Binding of the ligand (TGFβ-1, -2, or -3) to the type
II receptor triggers formation of heteromeric type I-type II receptor complex, that propagates
the TGF-β responses (reviewed in Derynck, R. and Feng, X., 1997). In the resulting
complex, the type II receptor phosphorylates and activates the type I receptor. Activated type
I receptor then phosphorylates the intracellular mediators of TGF-β signaling Smad2 or
Smad3 proteins at SSXS motif present in their C-terminal domains. This, in turn, triggers the
oligomerization of Smad2 or –3 with their common partner, Smad4 (Nakao, A. et al, 1997;
Lagna, G. et al, 1996). The resulting Smad protein complexes then migrate to the nucleus,
where they regulate the expression of TGF-β responsive genes. The RIII, also called
proteoglycan, is the most abundant TGFβ-1 binding molecule on the cell surface. Type III
receptor does not contain a consensus signaling motif, therefore the biological importance of
RIII in vivo has not been defined. It has been proposed that RIII enhances TGFβ-1 binding to
RII by directly presenting the ligand to RII (Lopez-Casillas, F. et al, 1993; Moustakas, A. et
al, 1993). Expression of RIII restores autocrine TGFβ-1 activity in MCF-7 human breast
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cancer cells (Chen, C. et al, 1997). In epithelial cells derived from the breast, skin, and lung,
TGF-β rapidly elevates expression of the cell cycle inhibitory proteins p15Ink4b and p21WAF1
(discussed in the section 2.1) (Sandhu, C. et al, 1997; Hannon, G. and Beach, D., 1994;
Reynisdottir, J. et al, 1995; Claassen, G.F. and Hann, S.R., 2000).

Interestingly, this

response is suppressed by c-myc (Warner, B. et al, 1999; Massague, J. et al, 2000). c-myc
itself is a target gene of TGF-β signaling. In response to TGF-β, c-myc is rapidly downregulated in MCF-10A human mammary epithelial cells, HaCaT keratinocytes, and other
epithelial cell types (Chen, C. et al, 2001). Two recent papers provided an important insight
into the complex regulation of p15Ink4b by TGF-β and Myc (Seoane, J. et al, 2001; Staller,
P. et al, 2001). Zinc-finger protein Miz-1, originally identified as a Myc-binding protein,
plays the key role in that regulation. In the complex with Miz-1, Myc can bind to the initiator
element of the p15Ink4b promoter and inhibit its transcriptional activation by preventing
recruitment of the ubiquitous co-activator p300. Upon TGF-β treatment, Myc is rapidly
down-regulated. This, in turn, allows for the interactions of Miz-1 with other transcription
factors, such as Sp1, Smad3/4 on p15Ink4b promoter, which is proposed to generate a
nucleoprotein complex that constitute a platform for the recruitment of co-activators, basal
transcription factors, and RNA polymerase II. Hence, down-regulation of c-myc is required
for TGF-β mediated induction of p15Ink4b. In fact, suppression of the c-myc promoter by
TGF-β treatment through TGF-β control element (TCE) has been characterized (Pietenpol, J.
et al, 1991). In accordance with these results, it was shown that the loss of c-myc downregulation in mammary epithelial cells, MCF-10A, transformed with Ras/ErbB2 oncogenes
and MDA-MB-231 human breast cancer cell line coincides with a loss of TGF-β
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responsiveness of c-myc promoter (Chen, C. et al, 2000). In summary, these data suggest that
down-regulation of c-myc is a necessary event for the induction of p15Ink4b gene by TGF-β.
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5. Quinidine
Quinidine is a natural alkaloid found in the bark of the South American cinchona tree.
Of the more than 20 alkaloids found in the cinchona bark only quinidine and its stereoisomer quinine are now in use. The structure of quinidine is shown below. Quinidine is used
as an antiarrhythmic drug that acts to suppress abnormal heart rhythm, particularly atrial
fibrillation and flutter, paroxysmal atrial trachycardia, paroxysmal ventricular tachycardia,
and premature atrial and ventricular contractions (Katzung, B.G., 1984). These actions
probably result to a large extent from the quinidine’s ability to block sodium channels (Craig,
R.C. and Stitzel, R.E., 1994). Side effects include low blood pressure, skin rash, itching,
dizziness, and blurred vision. Quinidine also has an antimalarial activity, but because of its
superior absorption only quinine is used for the treatment of malaria. The exact mechanism
by which quinidine and quinine exert their antimalarial activity is not known.
Our previous studies established quinidine as an antiproliferative agent in human breast
cancer cell lines (Woodfork, K.A., 1995; Wang, S., 1998; Zhou, Q., 2000). The studies
reported here focused on further characterization of molecular mechanisms underlying the
antiproliferative effects of quinidine.

Quinidine
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6. G0-G1-S Cell Cycle Regulation in MCF-7 Cells by Potassium Channel Blocking
Drugs.
An important role of potassium channels in regulating cell proliferation has been reported
in a number of cell lines (reviewed by Dubois, J. and Rouzaire-Dubois, B., 1993; Nilius, B.
and Droogmans, G., 1994). Previous studies in Dr. Strobl's and Dr. Wonderlin's laboratories
indicate that potassium channel blocking agent, quinidine causes G1/G0 cell cycle arrest and
inhibition of proliferation in MCF-7 human breast cancer cell line (Woodfork, K. et al,
1995). Wodfork, K. et al, demonstrated that quinidine inhibits proliferation and causes
G1/G0 arrest with the same dose dependence with which it depolarizes the membrane
potential of MCF-7 cells. In addition, she identified the ATP- sensitive potassium channels
(KATP) as the target of quinidine, since only the agents that inhibited KATP were able to
produce G1/G0 cell cycle arrest and inhibition of proliferation (Woodfork, K., et al, 1995).
The work by Klimatcheva, K. described a linear hyperpolarized (LH) potassium current,
inhibited by quinidine, which is required for progression of MCF-7 cells through the G1
phase of the cell cycle. Interestingly, this current is overexpressed in MCF-7 cells
transformed with Ha-ras oncogene (Klimatcheva, E. and Wonderlin, W., 1999). This notion
is consistent with the reports by other investigators showing that expression or activity of K
channels correlates with the degree of cell proliferation in several other cell types (Wang, L.
et al, 1997; Nilius, B. and Wohlrab, W.,1992; Reichelt, W., 1989). Collectively, these studies
support a model where hyperpolarization of the membrane potential by transient activation of
the linear hyperpolarized current might be required for progression through the restriction
point in G1 (D point) and entry into S phase. Accordingly, inhibition of LH current by
blockade of KATP in response to quinidine, will prevent hyperpolarization of membrane
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potential and cells will become arrested at the D point. In support to this model, a large body
of evidence has shown that progression through the cell cycle is associated with changes in
intracellular ionic concentrations, which can be regulated by the changes in the membrane
potential (Whitaker, M. and Patel, R. 1990; Whitfield, J. et al, 1987). Intracellular ions, in
turn, initiate signal transduction pathways that lead to the activation of proliferation. For
example, increase in intracellular Ca2+ activates CREB transcription factor that stimulates
transcription of growth promoting genes (Sheng, M. et al, 1991). Several immediate-response
genes were shown to be induced by calcium agonists (reviewed in Roche, E. and Prentki, M,
1994). Treatment of human promyelocytic leukemia cells (HL-60) with the calcium
ionophore A23187 caused an increase in c-myc mRNA levels to 170 % of control cells
within an hour (Salehi, S., and Niedes, J., 1990). The putative intracellular calcium
antagonist TMB-8 inhibited both c-myc expression and DNA synthesis in a dose-dependent
manner in the Nb2 lymphoma cells (Murphy, P., 1988). It has also been shown that calcium
influx is a very early signal transduction that precedes the specific induction of the c-myc
proto-oncogene in lymphocytes (Liburdy, R., 1993).
The goal of studies presented here was to further understand the mechanism of G1/G0
cell cycle arrest and inhibition of cell proliferation in response to quinidine. The molecular
mechanism of c-myc gene regulation by quinidine in human tumor and normal breast
epithelial cell lines were studied. Effects of quinidine on c-Myc protein and mRNA levels, as
well as c-myc promoter activity were examined. Furthermore, the long-term effects of
quinidine in breast tumor cell lines were tested.
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7. Research Objectives
Previous studies in this laboratory demonstrated that quinidine causes early G1/G0 arrest
and inhibits proliferation in MCF-7 cells. The goal of these studies was to understand the
molecular mechanisms of c-myc gene regulation by quinidine in human breast cancer cells.

1. In the first series of experiments I tested the hypothesis that quinidine causes rapid
decrease of c-myc mRNA and protein levels during the G0/G1 transition in human
breast cancer cells. Four different breast cancer cell lines (MCF-7, MCF-7ras, MDA-231,
MDA-435) and normal breast epithelial cell line (MCF10A) were used.

2. Secondly, I tested the hypothesis that quinidine suppresses c-myc promoter activity.
Effects of quinidine on c-myc promoter were examined in a transient reporter gene assay,
using human c-myc promoter-luciferase constructs. Quinidine responsive region (QRR) of cmyc promoter was described. The role of TGF β1 and Sp1/Sp3 responsive elements located
within QRR was examined.

3. Finally, I studied the long-term effects of quinidine. Three important questions were
addressed:
3.1

Does quinidine induce differentiation in breast cancer cells

3.2

Does quinidine selectively inhibit growth in breast cancer, but not in normal
breast epithelial cells

3.3

Whether a specific down-regulation of c-myc by antisense oligonucleotides is
sufficient to cause quinidine-induced phenotype in breast cancer cells

45

II. MATERIALS AND METHODS

1. Materials
1.1. Cells
MCF-7 cells and MDA-MB-231 cells were provided by Dr. Marc Lippman
(Lombardi Cancer Center, Georgetown University). The MCF-7 cells transformed with the
H-ras oncogene (Kasid, A. et al, 1985) were provided by Dr. Robert Dickson (Lombardi
Cancer Center, Georgetown University). MDA-468 cells were obtained from the American
Type Culture Collection. MDA-MB-435 and T47D cells were provided by Dr. Mike Miller
(Department of Biochemistry, West Virginia University) and Dr. Michael Moore
(Department of Biochemistry, Marshall University), respectively. Normal human mammary
epithelial cells HMEC and MCF10A were obtained from Clonetics (San Diego, CA) and
American Type Culture Collection, respectively.

1.2. Drugs/Hormones/Oligonucleotides
Quinidine-HCl was purchased from Sigma Chemical Co. (St. Louis, MO).
Concentrated stock solutions (10mM) were prepared fresh for use by dissolving in sterile
water. Seven µl of 10N HCl/ml of the stock solution was used. Estradiol-17β (Steraloids,
Wilton, NH) was dissolved in 95% ethanol at a concentration of 2mM and diluted 1:106 in
the medium to get the final concentration of 2nM. TGFβ1 (R&D Systems, Minneapolis, MN)
stock solution (2.5µg/ml) was prepared by dissolving in 4mM HCl, 1mg/ml BSA and stored
at -20°C. c-myc antisense (5'-AACGTTGAGGGGCAT-3') and sense oligonucleotides (5'ATGCCCCTCAACGTT-3') were purchased from Sigma-Genosys (Woodlands, TX) and
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diluted in sterile water to yeild concentrated stock solutions of 175 µM. The stock solutions
were stored at -20°C for 2 months.

1.3. Plasmids
The human c-myc probe used for Northern blots was a 9 kb EcoR1-Hind III genomic
fragment spanning exons I and II and intron I isolated from the plasmid pHSR-1 obtained
from the American Type Culture Collection (Alitalo, K, et al, 1983). The reporter plasmids
containing different regions of the human c-myc promoter linked to the firefly luciferase gene
were kindly provided by Dr. Bert Vogelstein, Johns Hopkins University (He, T. et al, 1998).
The structures of myc-luciferase plasmids were confirmed by DNA sequencing. The human
cyclin D1- luciferase plasmid (1745CD1-Luc) was kindly provided by Dr. Richard Pestell
(The Albert Einstein College of Medicine, Bronx, NI) (Albanese, C., et al, 1995)

1.4. Antibodies
The Ki-67 (MIB-1, Ab-1) antibody (Oncogene Science, Cambridge, MA) was used at
a dilution of 1:50. The c-Myc antibody (9E10, sc-40), which reacts specifically with c-Myc
p67 of human origin and β-catenin (E-5, sc-7963) antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) were used at a dilution of 1:200 and 1:3000, respectively. A peroxidaseconjugated anti-mouse IgG (sc-2005, Santa Cruz) was used as the secondary antibody at a
1:2000 dilution for Western blots. A biotinylated anti-mouse IgG (H+L) (BA-2000, Vector
Laboratories, Inc.) was used as the secondary antibody at a 1:125 dilution for Ki-67
immunohistochemstry. The fluorescein-conjugated phalloidin antibody (Sigma) was used at a
1:200 dilution of a 5 µg/0.1ml solution in the Nile Red assay.

47

1.5. Stains
The fluorescent lipid stain, Nile Red (Sigma) was used at a 1:10,000 dilution of a
1mg/ml acetone solution. The Oil Red O (Sigma) stock solution was prepared by dissolving
2.5 g of the Oil Red O in 500 ml of 98 % Isopropanol. The working solution was prepared
fresh each time by diluting the stock solution in water at a 3:2 ratio. The working solution
was filtered once through the P5 Fisherbrand Filter paper (09-801D, Fisher Scientific).

2. Methods
2.1. Tissue culture
MCF-7 cells between passages 40-50, MCF-7ras, T47D, MDA-MB-231, and MDAMB-435 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (HyClone Laboratories, Inc, Logan, Utah), 2 mM glutamine, and 40 µg/ml
gentamicin. Experiments were performed in DMEM supplemented with 5% FBS. The cells
were maintained at 37 °C in a humidified atmosphere of 94% air, 6% CO2. Cells were
passaged every 5-6 days (about 70-80% confluent) at a 1:5 (MCF-7 and T47D) or 1:10
(MCF-7ras, MDA-MB-231, and MDA-MB-435) ratio. Normal human mammary epithelial
cells HMEC and MCF10A were grown in MEGM medium according to the directions from
suppliers. HMEC were grown from frozen stocks and used for 1-3 passages only. All cells
were counted using a hemocytometer. Cell viability was determined by trypan blue exclusion
(0.02 % trypan blue).
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2.2. Flow cytometry
Cell cycle phase distribution was anyalysed using the propidium iodide staining
method of Vindelov and Christensen, 1994. Briefly, confluent cells were plated in DMEM +
5% FBS at the density of 6x105/60 mm2 dish. Cells were allowed to attach for 5 hours, then
cell monolayers were rinsed twice with 1xHBSS (5.4 mM KCl, 108 mM NaCl, 0.34 mM
Na2HPO4 x 7H2O, 4.2 mM NaHCO3, 0.44 mM KH2PO4, pH 7.2) buffer to remove all traces
of the medium and 5 ml of fresh phenol red free PRF-DMEM containing 2% of the
charcoal/dextran treated FBS (2% stripped serum) was added. The medium was changed two
more times 20 and 30 hours later to facilitate removal of the endogenous estrogens present in
the cells. The total incubation period of the cells in the 2% stripped medium was 40 hours,
similar to the conditions described in the literature (Dubik, D. and Shiu, P., 1992). Finally, at
the end of the 40 hours, fresh 2% stripped medium +/- drugs was added to the cells. At the
end of the treatment, for each sample, cell medium was collected in a 15 ml conical tube.
Cells were harvested by trypsinization, placed into the same tube and counted by
hemocytometer. For each sample, 5x105 cells were pelleted, washed with 1x HBSS, pelleted
again, and resuspended in 250 µl of lysis buffer (3.4 mM trisodium citrate dihydrate, 0.1%
Nonidet P-40, 1.5 mM spermine-4HCl, 0.5 mM Tris base, 0.03 mg/ml trypsin, and 34 µM
EDTA). Cells were incubated for 25 min at 37 °C, then 500 µl of trypsin inhibitor/RNAse
solution (3.4 mM trisodium citrate dihydrate, 0.1% Nonidet P-40, 1.5 mM spermine-4HCl,
0.5 mM Tris base, 0.5 mg/ml trypsin inhibitor, 0.1mg/ml ribonuclease A) was added for 15
min at 37 °C. Finally, 500 µl of propidium iodide solution (3.4 mM trisodium citrate
dihydrate, 0.1% Nonidet P-40, 4.8 mM spermine-4HCl, 0.5 mM Tris base, 74.8 µM
propidium iodide) was added and cells were incubated at 37 °C for 10 min. Samples were
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kept on ice up to 24 hours. Flow cytometric analysis of cell cycle distribution was done on
FACScan (Becton Dickinson, San Jose, CA) using CellFIT software.

2.3. Western blots
Cells were rinsed with 1x PBS (phosphate buffered saline: 137 mM NaCl, 2.7 mM
KCl, 4.3 mM Na2HPO4 x 7H2O, 1.4 mM KH2PO4, pH 7.3) and harvested by scraping in a
boiling Western lysis buffer (1% SDS, 10 mM Tris, pH 7.4). Cells lysates were transferred
by 1cc syringe into 1.5 ml tubes, passed through the syringe three times, and boiled for 5
min. Supernatants were collected by spinning samples at maximal speed for 5 min in
microcentrifuge at 4°C. Twenty µl aliquots were removed for determination of protein
concentrations by BCA assay (bicinchoninic acid, Pierce, Rochford, IL) according to the
manufacturer’s protocol. Dithiothreitol (DTT) and protease inhibitors were added to the final
concentrations indicated: DTT (1mM), PMSF (phenylmethylsulfonyl fluoride, 0.1 mM),
aprotinin (1 µg/ml), and leupeptin (1 µg/ml). Extracts containing 60-90 µg of proteins were
diluted 4:1 with 5x Western sample buffer (3.125 ml of 1M Tris-HCl, pH 7.0, 5 ml Glycerol,
1 g SDS, 100 µl of saturated Bromophenol Blue solution, q.s. 10 ml with water; 12.5 µl of 2Mercaptoethanol/100 µl was added to the 5x buffer fresh each time). Proteins were denatured
by heating at 100 °C for 3 minutes immediately prior to loading onto 10 % polyacrylamide
gels. Proteins were separated and transferred to PVDF (polyvinylidene difluoride)
membranes (NOVEX, San Diego, CA) To reduce non-specific binding of antibodies,
membranes were incubated in Western blocking buffer (3% non-fat dry milk in Tris-buffered
saline-Tween 20 (TBST): 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.05% (v/v) Tween 20)
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overnight at 4 °C. On the next day, membranes were washed 3 times (5 minutes each wash)
with Western washing buffer (0.1% non-fat milk, 0.1% chick ovalbumin, 1% FBS, 0.2%
(v/v) Tween 20 in PBS, pH 7.3). All washes were performed at room temperature using an
Orbital shaker (Bellco Glass, Inc., Vineland, New Jersey). After the washing, membranes
were incubated inside the Kapak heat sealable pouches (Kapak Corporation, Minneapolis,
MN) for 3.5 hours at room temperature on a rocker with primary antibody diluted in washing
buffer. At the end of the incubation, membranes were washed 3 times (5 minutes each) with
Western washing buffer and once with TBST buffer. The membranes then were incubated for
40 min on a rocker at room temperature with peroxidase-conjugated secondary antibodies
diluted in TBST. After that, membranes were washed 3 times (10 minutes each wash) with
TBST. The specific protein signals (Myc or β-catenin) were visualized using
chemiluminescent peroxidase substrate (Super Signal, Pierce, Rockford, IL) for 7 minutes
and exposing the membranes to the Kodak X-OMAT film (Eastman Kodak Co., Rochester,
NY). Autoradiographic signals were quantified by densitomery (Personal Densitometer SI,
Molecular Dynamics, Sunnyvale, CA) and Image QuaNT software, version 4.1. Myc signals
were normalized to the 97 kDa β-catenin protein signals.

2.4. Northern blots
Total cellular RNA was purified by the method of Chomczynski and Sacchi
(Chomczynski, P. and Sacchi, N., 1987). Briefly, cells were harvested by scraping in
2.5ml/T-75 flask of ice-cold RNA harvesting buffer (4M guanidinium thiocyanate, 25mM
sodium citrate, pH 7.0, 0.1M 2-mercaptoethanol, 0.5% N-laurylsarcosine) and transferred
into pre-cooled sterile 15ml conical tubes. All of the following steps were performed on ice.
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Cellular DNA was sheared by passing the cell lysates through a 22 gauge needle with a 5ml
syringe. Two hundred and fifty µl of 2M sodium acetate, pH 4.0, 2.5 ml of water-saturated
phenol, and 1ml of chloroform were added and mixed thoroughly by shaking. The lysates
were incubated on ice for 30 minutes and centrifuged in a Sorvall H-1000B rotor at 3,500
rpm for 15 min at 4 °C. The upper aqueous phase containing the RNA was carefully
transferred into a clean 15ml conical tube. The white interphase containing proteins and
DNA should be avoided. RNA was then precipitated by adding 2.5ml volumes of
isopropanol and incubating at -20°C overnight. Precipitated RNA was collected by
centrifuging for 30 min in a Sorvall H-1000B rotor at 3,500 rpm at 4 °C. The supernatant was
discarded; the RNA pellet was resuspended in ice-cold 75 % ethanol, and transferred to a
clean Eppendorf tube. The RNA solution was spun in an Eppendorf microcentrifuge at
maximal speed for 10 minutes at 4 °C. The supernatant was removed and the RNA pellet was
dissolved in an appropriate amount of DEPC (diethyl pyrocarbonate) -treated water. Two µl
of RNA from each sample was dissolved in 998 µl (1:500 dilution) of the DEPC water and
their absorbency at 260 nm was measured using a spectrophotometer (DMS 80 Varian,
Australia). To quantify RNA concentration (in µg/µl), the optical density reading was
divided by 24 and multiplied by 500 (the dilution factor). Fifteen µg of RNA for each sample
was mixed with 5x RNA sample buffer (0.75 ml deionized formamide, 0.15 ml 10x MOPS
(3-[N-morpholino] propanesulfonic acid), 0.24 ml 37 % formaldehyde, 0.14 ml RNase-free
water, 0.1 ml glycerol, 0.04 ml 10 % bromophenol blue) at a ratio of 4:1. RNA was separated
on 1.2% agarose-1.9 % formaldehyde gels in MOPS running buffer (20 mM MOPS, 5 mM
sodium acetate, 0.5 mM EDTA, pH 8.0), and transferred to 0.2 mm nitrocellulose paper
(Schleicher and Schuell, Keene, NH) by capillary action. Membranes were air-dried for 5
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minutes and baked in a vacuum oven at 80 °C for 2 hours to fix the RNA. After that, the
membranes were incubated in the pre-hybridization solution (50% formamide, 250 mM
NaHPO4, pH 7.2, 250 mM NaCl, 1 mM EDTA, pH 8.0, 1mg/ml of denatured salmon sperm
DNA, 7% SDS) in the Micro-hybridization oven (Bellco Glass Inc., Vineland, NJ) at 42 °C
for 15-20 hours to decrease non-specific binding of the probe. Next, the pre-hybridization
solution was exchanged with the hybridization solution (the same pre-hybridization solution
plus denatured c-myc DNA fragment labeled with [αP32]dCTP by random priming
(Rediprime DNA labeling kit, Amersham Corp., Arlington Hts., IL). About 1.5-2 x 106 cpm
of the probe/ml of the hybridization mix was used. Hybridization reactions were performed at
42°C for 40-42 hours, then blots were washed in 2x SSC (Standart Saline Citrate)-0.1% SDS
solution twice for 20 minutes each wash at 37°C. A high stringency wash of the c-myc probe
was performed for 15 minutes at 42°C in 0.1x SSC-0.1% SDS buffer. Blots were exposed in
a phosphorimager cassette. Quantitative analysis of the hybridization signals was performed
using PSI-PC (Molecular Dynamics, Sunnyvale, CA) and ImageQuaNT software, version
4.1. Hybridization signals were normalized to levels of 18S or 28S RNA in the ethidium
bromide stained gels.

2.5. Reporter gene assay
Transient transfection procedure. All plasmids used in the reporter gene assay were
purified using Qiagen DNA purification columns, according to the manufacturer’s protocols.
On day one, confluent MCF-7 cells were re-plated at the density of 8x105/60 mm2 tissue
culture dish in 5 ml DMEM/5%FBS medium. After 20-24 hours, when cells reached about
40-50 % confluency, cell monolayers were rinsed with 1xHBSS (Hank's Balanced Salt
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Solution) buffer and 5ml of DMEM/2%FBS medium were added. One hour later,
transfections were started by adding the transfection mixes to the cells. The transfection
mixes were prepared in a sterile 3ml glass tubes by mixing 5 µg of plasmid DNA, 30 µl of
the DOTAP liposomal transfection reagent (1811177, Roche Molecular Biochemicals), and
water to the final volume of 150 µl for each sample. This volume was calculated to carry out
transfections in 60 mm2 dishes, in 5ml medium. Transfection mixes were incubated at room
temperature for 15 minutes. Transfections were terminated 6-7 hours later by exchanging the
medium with fresh medium +/- drugs.
Luciferase Assay. Cells were harvested 24 hours after the end of transfections by
scraping into ice-cold lysis buffer (25 mM Tris-phosphate, pH 7.8, 1% Triton X-100, 2mM
EDTA, 10% Glycerol). All the following steps were performed on ice. Cell lysates were
transferred into 1.5 ml Eppendorf tubes and spun in the Eppendorf microcentrifuge at
maximal speed for 5 minutes at 4°C. The supernatants were transferred into clean tubes.
Aliquots of 20 µl were removed for determination of protein concentrations by BCA assay.
To measure luciferase activity, 50 µl of cell extracts were added to 250 µl of ice-cold
luciferase sample buffer (25 mM glycylglycyl, pH 7.8, 15 mM MgSO4) in 12x75 mm
polypropylene culture tubes (60818-430, VWR Scientific, West Chester, PA). Immediately
before measuring the luciferase activity, the samples were warmed to 25 °C (the optimal
temperature for luciferase enzymatic activity). Luciferase activity was measured using an
Auto Luminat (LB 953, EG and G-Bertholdt) equipped with a dual injection system. The
reactions were initiated by automatic injections of 100 µl of ATP solution (25 mM
glycylglycyl, pH 7.8, 15 mM MgSO4, 20 mM ATP) and 100 µl of the luciferin solution (25
mM glycylglycyl, pH 7.8, 1 mM luciferin) into each sample. The production of the light was
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measured. The following luminometer settings were used: incubation temperature =25 °C,
reading time =6 seconds, injection amount =100µl. The ATP solution was placed in the
measuring position 1, and the luciferin solution was placed in the measuring position of the
luminometer. The relative luciferase units obtained from 50 µl of cell extracts were
normalized to 200 µg of cellular proteins. Light generation from purified luciferase (Sigma)
was used as the standard in each experiment to ensure that all determinations were performed
under linear assay conditions. The amount of sample buffer, lysis buffer, and purified
luciferase used for the standard curve are given in the Table below.

Sample buffer (µl)

Lysis buffer (µl)

5 pg/µl luciferase solution (µL)

250

50

0

248

50

2 (10 pg)

246

50

4 (20 pg)

242

50

8 (40 pg)

234

50

16 (80 pg)

218

50

32 (160 pg)
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2.6. Ki-67 immunohistochemistry.
MCF-7 cells were plated at the density of 2x105/ 35 mm2 tissue culture dish on sterile
glass cover slips in 3 ml of DMEM/5%FBS +/- drugs. At the end of the treatment, the
medium was removed by aspiration and cells were fixed by transferring the cover slips to a
- 20°C fixing solution (50% acetone/50% ethanol) for 10 minutes on ice. All the following
steps were performed at room temperature. Cells were rinsed with the working PBS (wPBS)
solution (1x PBS, 0.15 % bovine serum albumin), and freshly made Blocking solution #1
(1:100 dilution of 30% H2O2 in methanol) was added to the cells for 15 minutes to block
endogenous peroxidase activity. Cells were rinsed with wPBS, and then Blocking solution #2
(10% horse serum in wPBS) was added for 30 minutes to block non-specific binding of
antibodies. The blocking solution was carefully removed, leaving a thin layer of it on the
cover slips, and 500 µl/cover slip of diluted Ki-67 antibody (1:50 ratio in wPBS) were added
for one hour. Cells used for the negative control remained in the blocking solution #2. Ki-67
antibody was removed by rinsing cells with wPBS for 5 minutes and biotinylated anti-mouse
IgG secondary antibody (1:125 dilution in wPBS) was added for 30 minutes. The BiotinAvidin solution (B/A) was prepared 30 minutes prior to use by adding 1 drop of each
Reagent A and B (PK-6100, Peroxidase Vectastatin Elite ABC kit, Vector Laboratories,
Inc.). The secondary antibody was removed by rinsing cells with wPBS for 5 minutes and
B/A solution was added for 30 minutes. After that, cells were rinsed with wPBS for 5
minutes and a peroxidase substrate, DAB (750118, Research Genetics, Inc.) was added for
10 minutes. Cells were rinsed with wPBS and counterstained with Mayer’s hematoxylin
(Sigma) for 1-2 minutes to visualize cell nuclei. Cover slips were mounted with Permount
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solution (SP15-100, Fisher Scientific). The images were obtained using an Ortholux
microscope (Ernst Leitz Wetzlar, Germany) (40x objective). Cells were scored using ImagePro Plus software (Media Cybenetics, Silver Spring, MD).

2.7. Oil-Red O assay
Cells were plated in 35 mm2 tissue culture dishes on sterile glass cover slips in
DMEM/5%FBS +/- drugs. At the end of the treatment, the cover slips were transferred into
60 mm2 glass dishes containing 3 ml of cell fixative solution (10% formaldehyde and 0.2%
calcium acetate in PBS) for 3 minutes. The fixative was removed by aspiration and 3 ml of
freshly made Oil-Red O working solution (Oil-Red O stock solution [0.5 % Oil-Red O in
98% Isopropanol] diluted in water in a 3:2 ratio) were added for 10 minutes. Cells were then
rinsed in water and counterstained with Mayer’s hematoxylin solution (Fisher, Pittsburgh,
PA) for 1 min at room temperature. Cells were briefly washed in 0.4 % NH4OH, rinsed in
distilled water, and then mounted with 50% glycerol solution (a filtered 1:1 dilution of
Glycerol in water). The images were obtained using Ortholux microscope (Ernst Leitz
Wetzlar, Germany) (40x objective). Cells were scored using Image-Pro Plus software (Media
Cybenetics, Silver Spring, MD).

2.8. Nile Red staining
Cells were plated at the density of 1x105/ 35 mm2 dishes on sterile glass cover slips
and grown for 96 hours in DMEM/5%FBS +/- drugs. At the end of the treatment, cells were
fixed in 3.7% formaldehyde/PBS, rinsed in PBS, and then treated briefly with 0.4% Triton X100 in PBS. After rinsing 3 times in PBS, the cells on cover slips were incubated with
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fluorescein-phalloidin antibody (1:200 dilution of a 5µg/0.1 ml solution, Sigma) in the dark
for 40 minutes at room temperature. Cells were then rinsed with PBS and incubated for 5
minutes with the fluorescent lipid stain, Nile Red (1:10,000 dilution of a 1mg/ml acetone
solution, Sigma) (Greenspan, P. et al, 1985; Toscani, A. et al, 1990). The cover slips were
rinsed with PBS and mounted with Fluoromount-G containing 2.5% N-propyl galate to
minimize photobleaching. Images were obtained using a Zeiss Axiovert 100M confocal
microscope (63x objective).

2.9. MTS assay
Cells were plated in a 96-well dishes in DMEM/5%FBS +/- drugs at the following
densities, depending upon the relative growth rates of the cell lines: HMEC (2000), MCF-7
(1000), MDA-231 (500), T47D (1500). At the end of the treatment time, the medium was
removed by aspiration. One hundred µl of DMEM/5%FBS and 20 µl of the MTS reagent
(CellTiter 96 AQueous one solution cell proliferation assay, Promega Cor., Madison, WI)
were added to each well using a multichannel pipetteman. The plated cells were incubated
for 2 hours at 37 °C. Absorbency readings were obtained at a wavelength of 490 nm with a
microplate spectrophotometer (Molecular Devices).

2.10. Statistics
The SigmaPlot software (SPSS Inc., Chicago, IL), version 5.0 and JMP software
(SAS Institute, Inc., Cary, NC) were used for statistical analysis. One way analysis of
variance (ANOVA) followed by the Dunnett’s test for comparison of multiple groups with
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control or the Turkey-Kramer test for comparison between the different groups was used. A
significance level of 0.05 was used.
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III. RESULTS
1. Quinidine Reduces Myc Protein Levels in Human Breast Cancer Cells
1.1. Rapid suppression of Myc protein levels by quinidine in MCF-7 cells
Transient induction of c-myc mRNA and protein levels is a prerequisite for G0-G1
and G1 phase transition. According to our hypothesis, rapid suppression of Myc by quinidine
causes cell cycle arrest at the D point in the early G1 phase of the cell cycle due to the lack of
Myc-dependent transcription of the genes required for cells to pass through the D point. The
purpose of this experiment was to test how rapidly quinidine suppresses Myc protein.
MCF-7 cells were grown in T-75 tissue culture flasks until 95-100 % confluency (1.5-2
x 107 cells/T-75) in order to obtain a population of cells largely (85%) in G0/G1 phase
(Wang, S., et al, 1998). Before plating, the viability of the cells was assayed using a
hemocytometer to obtain cell counts and trypan blue dye to detect the dead cells. The
viability ranged from 96 to 100 %. The synchronized cells were then plated at the density of
3.5 x 106 viable cells per 100 mm2 tissue culture dish in 10 ml of DMEM/5% FBS medium.
90 µM quinidine or H2O (vehicle) was added to the dishes. One dish of each, control and
quinidine-treated cells was harvested in protein harvesting buffer 0, 60, 90, 120, 180 min
after the plating. Equal amounts of proteins (60 to 90 µg depending on the experiment) were
loaded into each well of 10 % polyacrylamide gels. As shown in Figure 6, a transient
increase in Myc protein levels occurs after sub-cultivating confluent MCF-7 cells in fresh
medium (release from the high cell density condition). The maximal increase in Myc protein
levels was 15-fold, achieved at 90 min after plating. This rise in Myc protein was suppressed
by quinidine, with the maximal level of suppression (60%) achieved at 60 min. The data
indicate that suppression of Myc protein levels occurs rapidly, and precedes the quinidine-
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induced cell cycle arrest (see Figure 3). This observation is a critical evidence in support to
our hypothesis that quinidine acts on Myc early in the G1 phase of the cell cycle, prior to cell
cycle arrest. Therefore, suppression of Myc protein by quinidine is not simply a result of cell
cycle arrest, but, in contrary, may play a causative role in it.
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Figure 6. Quinidine suppresses Myc protein levels in MCF-7 cells.
Confluent (Cf) MCF-7 cells were sub-cultivated at 0 time in DMEM/5%FBS (solid bars) or
in DMEM/5%FBS containing 90 µM quinidine (hatched bars). Cells were harvested for
Western blot analysis at the times indicated. Myc protein signals were quantified by
densitometry and normalized to the β-catenin signals. Data shown in the bar graph are the
mean Myc protein signals +/- S.D. of n =3 experiments expressed as a percent of maximal
stimulation (at 1.5 hours). The differences between the percentages of control and quinidinetreated cells were statistically significant (p<0.05) at 1 and 1.5 hours. The gel scans below the
bar graph are a single representative experiment performed with 80 µg of cell extract
protein/lane.
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1.2. Suppression of Myc by quinidine in MCF-7 cells is not mediated by the
impediment of cell attachment.
Some cell lines growing in tissue culture (epithelial cells, fibroblasts) require their
attachment to the special surface for the proper cell cycling, while others (lymphocytes) can
grow in a suspension. Therefore, any condition, that affects attachment of cells to the growth
surface can influence cell progression through the cell cycle. In the experiment described
above, quinidine was added to the cells immediately after the plating. At this point most of
the cells were loosely attached to the tissue culture dishes. The purpose of current experiment
was to test the influence of quinidine on the attachment of MCF-7 cells. If quinidine impedes
cell attachment, then suppression of Myc by quinidine and subsequent cell cycle arrest could
be simply the results of quinidine’s effect on cell attachment.
Confluent MCF-7 cells were re-plated in 60 mm2 tissue culture dishes in 5 ml DMEM5% FBS at the density of 0.8x106 cells/dish. Cells were allowed to attach for 3 hours. Then,
the medium was changed to DMEM-2% FBS and 72 hours later cells were treated with: 1)
DMEM-2% FBS, 2) DMEM-5% FBS, 3) DMEM-5% FBS + 90 uM quinidine. Cells were
harvested 1 hour later. Seventy µg of proteins were loaded into each well of 10 %
polyacrylamide gels and Western blot assay was performed as described in the Materials and
Methods. As shown in Figure 7, MCF-7 cells growing in DMEM-2% FBS (low serum
condition) have very low Myc protein levels. Addition of DMEM-5% FBS to these cells
caused rapid (within 1 hour) induction of Myc protein. Ninety µM quinidine completely
abolished this effect. These results demonstrate that quinidine suppresses Myc protein levels
to the same extent in both attached (down to 36%, Figure 7) and loosely attached (down to
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38%, Figure 8) MCF-7 cells, suggesting that suppression of Myc by quinidine is not
mediated by quinidine’s effect on cell attachment.

64

Figure 7. Suppression of Myc by quinidine in MCF-7 cells is not mediated by the
impediment of cell attachment.
Confluent MCF-7 cells were sub-cultivated in DMEM-5% FBS, allowed to attach for 3 hours
and then incubated in DMEM-2% FBS (low serum conditions) for 72 hours. After that, cells
were treated for 1 hour with: DMEM-2% FBS (2%), DMEM-5% FBS (5%), or DMEM-5%
FBS + 90 uM quinidine (Qd). Myc protein levels after Western blot assay were determined
by densitometry and normalized to the β-catenin levels. Myc protein levels in DMEM-5%
FBS treated cells were set to 100%. The numbers above the bars show Myc levels in
DMEM-2% FBS and DMEM-5% FBS+Qnd treated cells relative to DMEM-5% FBS treated
cells. The bar graph data are the mean +/- S.D. of n=2 experiments performed in duplicates.
The gel scans below the bar graph are a single representative experiment.
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1.3. Rapid suppression of Myc protein in other breast cancer cell lines
The purpose of this experiment was to assay whether the rapid decrease of Myc
protein by quinidine is specific to MCF-7 cells or is more general response of breast tumor
cells to quinidine. Three other cell lines used in this experiment were: MCF-7ras, MDA-MB231, and MDA-MB-435. MCF-7ras cells have high, constitutive expression of Myc protein
due to the activated ras-MAP kinase pathway. MDA-MB-231 and MDA-MB-435 cells are
ERα-/ERβ+ and ERα-/ERβ-, respectively (Vladusic, E., et al, 2000). These two cell lines
were chosen to assay if the ER status influences the Myc response to quinidine. Confluent
cultures of the cells were re-plated in 100 mm2 dishes in 10 ml DMEM-5 %FBS at the
density of 3x106 cells/dish and treated with 90 µM quinidine or H2O (vehicle). Cells were
harvested one (MCF-7ras, MDA-MB-231, MCF-7) or two (MDA-MB-231, MDA-MB-435)
hours later. The two-hour time point for MDA-MB-435 and MDA-MB-231 cells was chosen,
because in these cell lines the maximum levels of Myc protein after the release of cells from
high density are reached at this time. Equal amounts of proteins (70 µg) were loaded into
each well of 10 % polyacrylamide gels. As demonstrated in Figure 7, quinidine suppressed
Myc protein levels by 82% (MCF-7ras), 65% (MDA-231), 62% (MCF-7), and 59% (MDA435) in these cell lines. The variance in control Myc levels of different cell lines (Figure 7 gel
scan) is in a good correlation with their proliferative rate (see Figure 18), which underlines
the role of Myc in cell proliferation. These results show that rapid decrease in Myc protein
levels by quinidine occurs in all four human breast cancer cell lines tested and is independent
of the ERs status.
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Figure 8. Quinidine suppresses Myc protein in MCF-7ras, MDA-231, and MDA-435
cells.
Confluent MCF-7, MCF-7ras, MDA-231, and MDA-435 cells were sub-cultivated in
DMEM/5%FBS +/- 90 µM quinidine. Cells were harvested at indicated time points and Myc
protein levels after Western blot assay were determined by densitometry in control (solid
bars) or quinidine-treated (hatched bars) cells. Myc signals were normalized to the β-catenin
signals. Myc protein levels in quinidine-treated cells expressed as a percent of the respective
controls for each cell line are shown above the hatched bars. The bar graph data are the mean
+/- S.D. of n =3 experiments with MCF-7 and MCF-7ras cells, and the mean +/- range in n
=2 experiments with MDA-231 and MDA-435 cells. The gel scans below the bar graph are a
single representative experiment performed with 70 µg of cell extract protein/lane.
∗ Significantly different from control values (p<0.05).
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1.4. Suppression of Myc protein by quinidine is sustained within 24-hour tested period
The objective of this experiment was to determine the character of Myc suppression
by quinidine: transient versus sustained. MCF-7 and MCF-7ras cells were re-plated from
confluent T-75 flasks at the density of 3 x 106 cells/100 mm2 tissue culture dish in 10 ml
DMEM/5%FBS medium. Zero, 30, or 90 µM quinidine was added to the cells. Twenty-four
hours later cells were harvested and 70 µg of proteins for each sample were separated on
10% polyacrylamide gels. As shown in Figure 9, quinidine caused concentration-dependent
reductions in the levels of Myc protein in both cell lines after 24 hours of treatment. Thirty
µM quinidine caused a more than a 50 % reduction in Myc protein levels in both cells,
compared with respective untreated control cells. Ninety µM quinidine further reduced Myc
protein levels by 88 % and 68 % in MCF-7ras and MCF-7 cells, respectively. The high levels
of Myc protein in the control MCF-7ras cells compared to MCF-7 cells are due to the
constitutive expression of the Myc in MCF-7ras cell line. In MCF-7 cells Myc is transiently
induced during the G0-G1 and G1 phase transition (Figure 6) and then stays at constant low
levels throughout the cell cycle (Figures 5 and 9).
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Figure 9. Suppression of Myc protein by quinidine.
Confluent MCF-7 and MCF-7ras cells were sub-cultivated in DMEM/5%FBS +/- different
concentrations of quinidine. Cells were harvested 24 hours later and Myc protein levels after
Western blot assay were determined by densitometry. Myc signals were normalized to the βcatenin signals. The bar graph shows Myc protein levels in MCF-7 (solid bars) and MCF7ras cells (hatched bars) as the mean +/- S.D. of n =4 (MCF-7) and n=3 (MCF-7ras)
experiments. The numbers above the bars indicate the average Myc signal (% of control).
The gel scans below the bar graph are a single representative experiment performed with 70
µg of cell extract protein/lane.
∗ Significantly different from control values (p<0.05)
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1.5. Quinidine does not affect Myc protein levels in normal mammary epithelial cell line
MCF10A.
The abnormal expression of c-myc was reported in 32% of breast cancers, suggesting
its importance in the genesis and/or progression of breast cancer. Hence, our findings that
quinidine inhibits Myc protein levels in four different breast cancer cell lines by 60-80% are
very promising. The goal of this experiment was to test the effect of quinidine on Myc
protein in MCF10A normal mammary epithelial cell line.
MCF10A cells were re-plated from confluent T-75 flasks at the density of 6 x 105
cells/60 mm2 tissue culture dish in 5 ml MEGM medium +/- 90 µM quinidine. Twenty-four
hours later, cells were harvested and 60 or 70 µg of proteins for each sample were separated
on 10% polyacrylamide gels. As shown in Figure 10, quinidine didn’t cause a significant
reduction in Myc protein levels in this cell line. As has been discussed earlier, one of the
major problems with current chemotherapeutic drugs for breast cancer treatment is their lack
of selectivity for tumor tissue and associated with it toxicity in normal tissues. That why, it is
important to show, that quinidine selectively inhibits Myc protein in breast cancer but not in
normal breast epithelial cell lines.
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Figure 10. Quinidine does not affect Myc protein levels in MCF10A normal mammary
epithelial cells.
Confluent MCF10A cells were sub-cultivated in MEGM +/- 90 uM quinidine. Cells were
harvested 24 hours later and Myc protein levels after Western blot assay were determined by
densitometry. Myc signals were normalized to the β-catenin signals. The bar graph shows
Myc protein levels in control (solid bars) and quinidine-treated (hatched bars) cells as the
mean +/- S.D. of n=3 experiments. The numbers below the gel scans indicate the Myc
protein levels in two 2 independent experiments.
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2. Quinidine Reduces c-myc mRNA Levels in Breast Cancer Cells.
2.1. Suppression of c-myc mRNA levels by quinidine in MCF-7 and MCF-7ras cells.
MCF-7 and MCF-7ras cells were re-plated from the confluent state into the T-75
tissue culture flasks at the density of 3.5 x 106/flask in 10 ml of DMEM/5%FBS. Cells were
treated with 0, 30, and 90 µM quinidine. Twenty-four hours later, total cellular RNA was
purified, separated on 1.2% agarose-1.9% formaldehyde gels, transferred to nitrocellulose
paper, and hybridized to the radiolabeled c-myc probe, as described in the Materials and
Methods. Fifteen µg of total RNA were loaded into each well. Quantitative analysis of the
specific c-myc hybridization signals was performed using a PSI-PC (Molecular Dynamics,
Sunnyvale, CA) and ImageQuaNT software, version 4.1. The c-myc mRNA signals were
normalized to 18S ribosomal RNA signals on the ethidium bromide stained gel. The results
are shown in Figure 11. Quinidine caused a concentration-dependent suppression of c-myc
mRNA levels in both cell lines. Thirty µM quinidine reduced c-myc mRNA levels by 53%
and 31% in MCF-7 and MCF-7ras cells, respectively. Ninety µM quinidine further reduced
c-myc mRNA levels by 78% in MCF-7 and 63% in MCF-7ras cells. These results suggest
that the quinidine-induced changes in Myc protein levels observed at 24 hours (Figure 9)
may be due to the quinidine-induced suppression in c-myc mRNA levels (Figure 11).
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Figure 11. Suppression of c-myc mRNA by quinidine.
Northern blots were performed using 15 µg of total cell RNA/lane isolated from MCF-7
(solid bars) and MCF-7ras (hatched bars) cells 24 hours following sub-cultivating of
confluent monolayers +/- 30 or 90 µM quinidine. The numbers above each bar represent cmyc mRNA levels in quinidine-treated cells as a percent of control. The c-myc mRNA P32
hybridization signals and the 18S ribosomal RNA signals from ethidium bromide stained gels
are shown below the bar graph. Results are from a single experiment.
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2.2. Suppression of estradiol-induced c-myc mRNA levels and cell cycle progression by
quinidine in MCF-7 cells.
Estrogen plays an important role in etiology of breast cancer. About 30-40% of human
breast tumors are dependent on estrogen for growth in initial state of the disease (van der
Burg et al., 1992). Stimulation of c-myc gene by estradiol in estrogen-dependent MCF-7 cells
is critical to initiate progression of cells through G1 phase of the cell cycle and to activate
cell proliferation (Prall, O. et al, 1998). c-myc mRNA is rapidly (within 1 hour) induced by 2
nM estradiol in MCF-7 cells (Dubik, D. and Shiu, R., 1988).
The objective of this experiment was to test if quinidine can suppress estradiol-induced
c-myc mRNA levels and cell cycle progression. MCF-7 cells were re-plated from the
confluent state into the T-75 tissue culture flasks at the density of 2.6x106/flask in 10 ml of
DMEM-5% FBS (for Northern blots) or into 60 mm2 tissue culture dishes at the density of
6x105/dish in 5 ml of DMEM-5% FBS (for flow cytometry). Cells were allowed to attach for
5 hours, then cell monolayers were rinsed twice with 1xHBSS buffer to remove all traces of
the medium and 10 ml (per T-75) or 5 ml (per 60 mm2 dish) of fresh phenol red free (PRF) DMEM containing 2% of the charcoal/dextran treated FBS (2% stripped serum) was added.
The medium was changed two more times 20 and 30 hours later to remove the endogenous
estrogens present in the cells. The total incubation period of the cells in the 2% stripped
medium was 40 hours, similar to the conditions described in literature (Dubik,D. and Shiu,
P., 1992). Finally, at the end of the 40 hours, fresh 2% stripped medium +/- drugs was added
to the cells. Control cells (C) received 0.01% ETOH (vehicle), estradiol-treated cells (E2)
received 2 nM estradiol, and cells treated with both estradiol and quinidine (Q+E2) received
2 nM estradiol + different concentrations of quinidine.
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For Northern blot total cellular RNA was isolated 1 hour after addition of the drugs.
Fifteen µg of RNA was loaded into each well and separated on 1.2% agarose-5.4%
formaldehyde gels. The RNA transfer to nitrocellulose paper, hybridization procedure, and
quantification of c-myc mRNA signals was performed as described in the experiment 2.1. As
shown in the Figure 12, quinidine caused rapid concentration-dependent suppression of
estradiol-induced c-myc mRNA levels in MCF-7 cells, with the maximum inhibition by 60%
achieved with 90 µM quinidine.
For cell cycle analysis cells were harvested 30 hours after addition of the drugs. Cell
nuclei were stained with propidium iodide and flow cytometry was performed as described in
Materials and Methods. The results are shown in Figure 13. Most (80%) of the control cells
were in G1/G0 phase of the cell cycle due to the low (2% stripped FBS) serum condition.
Only 11% of the control cells progressed into the S phase. Two nM estradiol caused a
significant increase in S phase cells (34 % of total) with a concomitant decrease in G1/G0
phase cell population (49% of total). Quinidine significantly (by 59%) suppressed estradiolstimulated S phase progression. Seventy-five percent of Q+E2 cells were arrested in G1/G0,
and only 14% reached S phase.
In summary, these results show that quinidine inhibits both estradiol-stimulated c-myc
mRNA levels and G1 to S phase progression in MCF-7 cells. There was a good correlation
between decreases in c-myc mRNA (60%) and S phase cells (59%) by quinidine, suggesting
the important role of c-myc in quinidine-induced cell cycle arrest.
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Figure 12. Suppression of estradiol-stimulated c-myc mRNA by quinidine.
Confluent MCF-7 cells were sub-cultivated in PRF-DMEM/2% stripped serum, and
estrogen-depleted by replacing this medium twice during the total of 40 hours time period.
Induction of c-myc mRNA by 2 nM estradiol +/- different concentrations of quinidine was
measured after 1 hour by isolating total cell RNA and Northern blotting. Myc mRNA signals
were normalized to the 28S ribosomal signal in the ethidium bromide stained gel. Data
shown on the bar graph are the mean +/- S.D. of n = 3, except for 30 and 50 µM quinidine
that are from a single experiment. Values for E2 and E2+Qnd treated groups are reported
relative to control group (control=1). The differences between the percentages of estradioland quinidine+estradiol-treated cells were statistically significant for 90 µM quinidine
(p<0.05).
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Figure 13. Suppression of estradiol-stimulated S phase progression by quinidine.
Confluent MCF-7 cells were sub-cultivated in PRF-DMEM/2% stripped serum, and
estrogen-depleted by replacing this medium twice during the total of 40 hours time period.
Cells were treated with Ctr-0.01% ETOH (vehicle), Qnd- 90 µM quinidine, E2- 2nM
estradiol, Qnd+E2- 90 µM quinidine + 2nM E2. Cell cycle phase distribution was analyzed by
flow cytometry 30 hours later. Data shown on the bar graph are mean +/- S.D. of n = 4
experiments.
∗ Significantly different from control cells (p<0.05)
# Significantly different from E2 cells (p<0.05)
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3. Quinidine Inhibits c-myc Promoter Activity.
3.1. Quinidine inhibits c-myc promoter activity in MCF-7 cells
To determine whether the suppression of c-myc mRNA levels is mediated by effects of
quinidine on the activity of c-myc promoter, transient transfection assays were performed in
MCF-7 cells using a myc-luciferase plasmid. The construct containing 2.8 kb human c-myc
promoter linked to the luciferase reporter gene (Del-1) was kindly provided by Dr. Bert
Vogelstein, Johns Hopkins University. MCF-7 cells were plated in 5 ml DMEM/5%FBS at
the density of 8 x105 cells per 60 mm2 tissue culture dish. Seventeen hours later, the medium
was replaced with PRF-DMEM/2% stripped FBS medium and, one hour later, transfections
were started using DOTAP transfection reagent and 5 µg of plasmid DNA according to the
procedure described in the Materials and Methods. Transfections were terminated in 6-7
hours by replacing the medium with fresh DMEM/5%FBS +/- different concentrations of
quinidine. Cells were harvested 24 hours later, when the maximal levels of myc-driven
luciferase activity occurred. Luciferase activity was measured in cell extracts containing 200
µg of proteins using an Auto Lumat (LB 953, EG and G-Bertholdt). Luciferase activity in the
cells transfected with transfection reagent alone or with promoterless construct was always
less then 0.01% of the activity in the control cells transfected with myc-luc construct. Light
generation from purified luciferase was used as the standard in each experiment to insure that
all determinations were performed under linear assay conditions. As demonstrated in
Figure14, quinidine treatment caused a concentration-dependent decrease in the activity of
the c-myc promoter. Ninety µM quinidine decreased c-myc promoter activity by 60%. This
experiment provide an evidence that the activity of c-myc promoter is suppressed over the
same range of quinidine concentrations that suppress levels of c-myc mRNA and protein.
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The next goal was to identify the minimal region of the c-myc promoter, a putative
quinidine responsive element (QRE), which is sufficient to confer quinidine responsiveness
of the c-myc promoter.
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Figure 14. Quinidine suppresses c-myc promoter activity.
Confluent MCF-7 cells were sub-cultivated, allowed to attach, transferred into PRFDMEM/2% stripped serum, and transfected with 5 µg/dish of 2.8 kb human c-myc promoterluciferase reporter plasmid or with the transfection mix alone (DOTAP). At the end of
transfection cells were incubated for 24 hours in DMEM/5%FBS + the indicated
concentrations of quinidine before preparing cell extracts for luciferase assay. Data shown
are the mean +/- S.D. of n =3 experiments (90 and 120 µM Qnd) and n=2 experiments (30
and 50µM Qnd). Luciferase activity was measured in extracts containing 200 µg of protein,
and the data expressed as a percent of luciferase activity in control cells (100%). Luciferase
activity in mock-transfected cells (DOTAP) was < 0.01% that of control cells.
∗ Significantly different from control (0 quinidine) cells (p<0.05)
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3.2. QRE is located within 168 bp region of the c-myc promoter between -100 and +68
with respect to P1.
To determine the minimal region of the c-myc promoter that is sufficient for quinidine
responsiveness, several c-myc promoter 5'-deletion mutants of the original Del-1 construct
were used. The mutant constructs were kindly provided by Dr. Bert Vogelstein, Johns
Hopkins University. Their structures are shown in Figure 15. These constructs were
transiently transfected into MCF-7 cells and their relative luciferase activities in response to
quinidine were assayed 24 hours later in an identical manner as described in 3.1. The basal
(control) levels of c-myc promoter activity varied among these mutant constructs (Figure
15B), presumably due to the presence of different negative and positive regulatory elements.
For example, the Del-1 has lower levels of basal luciferase activity compared to the Del-2
and Del-4, due to the presence of the negative repressor binding site in its promoter sequence
that correlates with DH I (see Table 2) located 1851 bp upstream of the P1. The lower levels
of basal promoter activity in the Frag-E compared to the Del-2 and Del-4 are explained by
the deletion of the five tandem CT-boxes (CCCTCCCC) located 101 bp upstream P1. These
CT-boxes are required to promote transcription from P1 and for maximal activity of P2 (see
Table 3). In all these deletion constructs quinidine inhibited c-myc promoter activity by 6070% (Figure 16A). In contrast, quinidine had a little effect on the promoterless construct
(Luc, Figure 16B), suggesting that effects of quinidine are specific for c-myc promoter. The
results from this experiment suggest that the putative QRE is located within 168 bp region of
the Frag-E construct, since this region was sufficient to confer quinidine responsiveness of
the c-myc promoter. This region contains two important cis-elements: the TGF β1 control
element (TCE) and region from -60 to -37 that contains Sp1/Sp3 binding site (see Table 3).
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The first element is involved in inhibition of c-myc P1 transcription initiation in response to
TGF β1, whereas the presence of intact second element is essential for P1 transcription. The
further fine mapping of QRE within the Frag-E using specific PCR primers could help in
understanding the importance of these binding sites in the quinidine-mediated regulation of
the c-myc promoter.
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Figure 15. The structures of the 5’-deletion mutants of the original Del-1 construct.
The gray and white rectangles represent c-myc promoter and luciferase coding region,
respectively. P1 and P2 are the sites of the transcription initiation from the respective
promoters. The restriction enzymes and their cut sites are shown above the Del-1 construct.
The locations of 5' and 3’-ends of the constructs are given with respect to the P1.
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Figure 16. Inhibition of c-myc promoter activity in 5'-deletion mutants of the Del-1 by
quinidine.
Confluent MCF-7 cells were sub-cultivated, allowed to attach, transferred into PRFDMEM/2% stripped serum, and transfected with 5 µg/dish of the different c-myc mutant
constructs. At the end of transfection cells were incubated for 24 hours in DMEM/5%FBS
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+/- 90uM quinidine before preparing cell extracts for luciferase assay. Luciferase activity
was measured in cell extracts containing 200 µg of protein.
A. Luciferase activities in quinidine-treated cells (hatched bars) are expressed as percent of
respective controls (solid bars) for each construct. Data shown on the bar graph are the mean
luciferase activity +/- S.D. of at least n=3 experiments.
∗ Significantly different from control values (p<0.05).
B. Luciferase activity in the cells transfected with Del-1 was set to 100%. Luciferase
activities in cells transfected with other construct are expressed relative to the Del-1. Cells
transfected with promoterless construct (Luc) always had luciferase activity less then 0.01%
of the activity in the control cells transfected with myc-luc construct. Data shown in the bar
graph represent the mean +/- S.D. of at least n=3 experiments.
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3.3. Quinidine does not affect activity of the cyclin D1 promoter
To examine the specificity of the effects of quinidine on the c-myc promoter, the
human cyclin D1 promoter linked to the luciferase reporter gene was used. MCF-7 cells were
transiently transfected with cyclinD1-luc construct in a similar procedure as described for the
myc-luc plasmids in the section 3.1. Transfection reactions were terminated by replacing the
medium with the fresh DMEM/5%FBS +/- 90 µM quinidine. Twenty-four hours later,
luciferase activity in cell extracts was measured. As shown in Table 4A, quinidine did not
cause significant changes in the activity of the cyclin D1 promoter. This is an important
control for the specificity of quinidine's effects on the c-myc promoter.

3.4. Quinidine does not affect enzymatic activity of purified luciferase protein
The reporter gene system allows one to measure the promoter activity of the gene of
interest. In this system the promoter sequence is linked to the reporter gene coding sequence.
As a result, any changes in the promoter activity would cause the corresponding changes in
the levels of the reporter protein, e.g. luciferase. The changes in promoter activity of the gene
of interest are measured indirectly by measuring enzymatic activity of the reporter protein.
Therefore, it is important to demonstrate that changes in the activity of particular promoter in
response to the drug treatment are not due to the direct effect of that drug on the enzymatic
activity of the reporter protein. In order to show that quinidine has no effect on the activity of
luciferase protein, the extracts of the control and quinidine-treated MCF-7 cells were used.
One hundred pg of purified luciferase protein was added to both cell extracts and the
luciferase activities in these samples were assayed in an identical manner as described for the
myc-luciferase construct in section 3.1. As shown in Table 4B, quinidine had no effect on the
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enzymatic activity of the purified luciferase protein. These results are important, because
they demonstrate that any quinidine-induced changes in the luciferase activity in the extracts
of cells transfected with the myc-luciferase construct (see Figure 14 and 16) are likely to be
due to the corresponding changes in the activity of the c-myc promoter.
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A. Effect of quinidine on the cyclin D1 promoter activity

Treatment
Control
Quinidine

Luciferase Activity (% of control)

100
120 (+/- 15.3)

B. Effect of quinidine on the enzymatic activity of purified luciferase

Treatment
Control
Quinidine

Luciferase Activity (% of control)
100
99 (+/- 1)

Table 4. Effect of quinidine on the cyclin D1 promoter and purified luciferase activity.
Confluent MCF-7 cells were sub-cultivated, transferred into PRF-DMEM/2% stripped
serum, and transfected with 5µg/dish of the human cyclin D1-luciferase plasmid (A) or with
transfection reagent alone (B). Transfected cells were incubated for 24 hours in
DMEM/5%FBS medium +/- 90 µM quinidine before preparing cell extracts for the luciferase
assay.
A. Luciferase activity was measured in extracts containing 200 µg of protein. Luciferase
activity in the quinidine-treated cell extracts is expressed as a percent of that in the control
cells (100%). Data shown are the mean +/- S.D. of n = 4 experiments.
B. 100 pg of the purified luciferase protein were added to the control and quinidine-treated
cell extracts containing 200 µg of proteins before luciferase activity was measured.
Luciferase activity in the quinidine-treated cell extracts is expressed as a percent of that in
the control cells (100%). Data shown are the mean +/- S.D. of n = 3 experiments.
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3.5. The role of TGFβ
β1 control element and Sp1/Sp3 binding site of a QRR in the
regulation of c-myc promoter by quinidine
The results from the experiment 3.2 suggest that putative QRE is located within 168 bp
region of the c-myc promoter. This region contains two important cis-elements: the TGFβ1
control element (TCE) and GC-rich region from -60 to -37 that contains Sp1/Sp3 binding site
(see Table 3). In the next series of experiments we tested the role of these elements in the
regulation of c-myc promoter by quinidine. In general, the regulation of gene promoter by
particular agent via a cis-element can be achieved by several mechanisms, some of which are
listed here: 1) by changing the binding of trans-acting factors to the element, without altering
their protein levels, 2) by changing the protein levels of trans-acting factors, 3) by binding
directly to the cis-element, preventing further binding of trans-acting factors.
Effects of quinidine on Sp1 and Sp3 protein levels in MCF-7 cells. The goal of this
experiment was to test if quinidine alters the levels of Sp1 and Sp3 proteins. Confluent MCF7 cells were re-plated in 60 mm2 dishes in 5 ml DMEM-5 %FBS at the density of 1x106
cells/dish and treated with 90 µM quinidine or H2O (vehicle). Cells were harvested 90 min
later for Western blot analysis. Equal amounts of proteins (10 µg for Sp1 and 20 µg for Sp3
gel) were loaded into each well of 7.5 % polyacrylamide gels. As shown in Figure 17,
quinidine didn’t change the levels of either protein. The results indicate that suppression of cmyc promoter by quinidine is not mediated by the changes in Sp1/Sp3 protein levels. This
does not exclude the possibility of Sp1/Sp3 involvement in regulation of c-myc promoter by
quinidine, since binding of these proteins to the GC-rich region of QRR but not their levels
could be responsive to quinidine. Sp1 and Sp3 are ubiquitous transcription factors that are
involved in regulation of a number of genes. Hence, changes in the levels of Sp1/Sp3
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proteins will affect expression pattern of all those genes. The Sp1 transcription factor can
regulate transcription by at least two mechanisms: 1) binding GC-rich sequence directly or 2)
indirectly interacting with other transcription factors to alter gene transcription (Porter, W. et
al., 1996). For example, Sp1 can form a complex with the ER, which then binds to DNA
regions containing both Sp1 elements and ERE-half sits (Porter, W. et al., 1996; Wu-Peng,
X. et al., 1992). Therefore, transactivating activity of Sp1 factor may be influenced by the
presence of other responsive elements next to the GC-rich region. Sequence analysis of
cyclin D1 promoter revealed a presence of two consecutive Sp1 binding sites between base
pairs –113 and –102. This Sp1-binding region has also been shown to bind Egr-1 (early
growth response protein-1) transcription factor. A dual interplay between Egr-1 and Sp1
response elements has been described for a number of promoters (Khachigian, L. et al., 1995;
Skerka, C. et al., 1995; Ebert, S. and Wong, D., 1995) including cyclin D1 promoter
(Guillemot, L. et al, 2001). In this model Egr-1 displaces Sp1 at the overlapping motifs to
activate transcription of its target genes (Khachigian, L. et al., 1995; Cui, M. et al., 1996) In
my experiments quinidine had a minimal effect on cyclin D1 promoter activity, indicating
that quinidine does not affect binding of Sp1 protein to the cyclin D1 promoter. The
preferential regulation of Sp1/DNA interaction in c-myc but not cyclin D1 promoter by
quinidine could be explained by the overlapping nature of Sp1/Egr sites of cyclin D1
promoter. This issue can be resolved by examining the changes in Sp1/DNA interaction of cmyc and cyclin D1 promoters in response to quinidine using electrophoretic mobility shift
assay.
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Figure 17. Quinidine does not change the levels of Sp1 and Sp3 proteins.
Confluent MCF-7 cells were sub-cultivated in DMEM/5% FBS +/- 90 uM quinidine. Cells
were harvested 90 min later and Sp1/Sp3 proteins levels after Western blot assay were
determined by densitometry. The β-catenin signals were used as a loading control. The bar
graph shows Sp1 (left panel) and Sp3 (right panel) proteins levels in control (solid bars) and
quinidine-treated (hatched bars) cells as the mean +/- S.D. of n=2 experiments.
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The role of TCE in regulation of c-myc promoter by quinidine. Normal human mammary
epithelial cells, MCF10A, respond to TGFβ1 treatment by rapid (within 2 hours) decrease in
Myc protein levels and subsequent inhibition of cell growth. These effects are abolished in
breast cancer cell lines and in MCF10A cells transformed with Ras/ErbB2 oncogenes (Chen,
C. et al, 2001). Down-regulation of c-myc promoter activity through TCE has been reported
to play a key role in TGFβ1 mediated growth inhibition in different cell lines (Pietenpol, J. et
al, 1991; Chen, C. et al, 2001). In order to test the role of TCE in the regulation of c-myc
promoter by quinidine, a series of experiments were performed to compare effects of
quinidine and TGFβ1 on proliferation and Myc protein levels in different cell lines.
MCF10A cells were re-plated from confluent T-75 flasks at the density of 6 x 105
cells/60 mm2 (for Western blot) or 1 x 105 cells/35 mm2 (for cell count) tissue culture dishes
in 5 or 3 ml MEGM medium, respectively. Cells were treated with: vehicle (4mM HCl,
1mg/ml BSA - 1µl/ml of medium), 90 µM quinidine, 5ng/ml TGFβ1, 90 µm quinidine +
5ng/ml TGFβ1. For Western blot assay, cells were harvested 24 hours later and equal
amounts of proteins (60 or 70 µg) for each sample were separated on 10% polyacrylamide
gels. For cell count assay, cells were harvested 72 hours later. As shown in Figure 18,
quinidine had little effect on cell number and Myc protein levels, whereas TGFβ1 caused a
significant reduction of both. Quinidine+TGFβ1 had additive effects on cell number and Myc
levels, which indicates that these agents work through the different pathways. Also,
quinidine, but not TGFβ1, inhibited growth of MDA-468, MDA-231, and MCF-7 breast
cancer cells (Figure 19). MDA-468 cell line has a defective TGFβ1 pathway due to the lack
of an important mediator of TGFβ1 signaling, Smad4 transcription factor (Chen, C. et al,
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2001). Jointly, these results suggest that regulation of c-myc and subsequently cell growth by
quinidine and TGFβ1 is mediated by different mechanisms in the described cell lines.
In summary, the results presented in this section imply that suppression of c-myc
promoter by quinidine is not mediated through TGFβ1 responsive element (TCE), due to the
different responses of cells to TGFβ1 and quinidine (Figures 18 and 19). By eliminating TCE
as a mediator of quinidine’s responses on c-myc promoter, the only other known regulatory
element remaining within the proposed 168 bp QRE is the GC-rich region. This region has
been shown to be essential for the transcription from the P1 promoter and can bind Sp1/Sp3
transcription factors. Our results showed that quinidine does not affect the levels of these
proteins (Figure 17). It is possible, that binding of these factors to the GC-rich region, but not
their levels are altered by quinidine.
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Figure 18. Quinidine and TGFβ
β1 have distinct effects on proliferation and Myc protein
levels in MCF10A cells.
Confluent MCF10A cells were sub-cultivated in MEGM +/- vehicle (4mM HCl, 1mg/ml
BSA - 0.5 µl/ml of medium), 90 µM quinidine, 5ng/ml TGFβ1, 90 µm quinidine + 5ng/ml
TGFβ1. Cells were harvested 24 (Western blot assay) and 72 (cell count assay) hours later.
Myc protein levels were determined by densitometry and normalized to the β-catenin signals.
The bar graph shows cell number (solid bars) and Myc protein levels (hatched bars) in
control and treated cells. The data in the table represent mean +/- STDEV of n=2
experiments.
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Figure 19. Quinidine and TGFβ
β1 have distinct effects on proliferation in normal
(MCF10A) and tumor (MDA-231, MDA-468, MCF-7) breast epithelial cell lines.
Confluent cultures of MDA-231, MDA-468, MCF-7, and MCF10A cells were sub-cultivated
at the density of 1x105 (MDA-231, MDA-468, MCF10A) or 2x105 (MCF-7) per 35 mm2
tissue culture dish in the presence of: C-vehicle (4mM HCl, 1mg/ml BSA - 0.5 µl/ml of
medium), Q- 90 µM quinidine, T-5ng/ml TGFβ1, T+Q-90 µm quinidine + 5ng/ml TGFβ1.
Cells were harvested 72 or 96 (for MCF-7) hours later and counted by hemocytometer. The
bar graphs show cell numbers as mean+/- STDEV of n=2 experiments.
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4. Quinidine Inhibits Growth and Induces More Differentiated phenotype in Human
Breast Cancer Cells
Another objective of this study was to determine the long-term effects of quinidine in
breast cancer cells. c-myc plays an important role in cellular differentiation. It has been
shown in many cells that down-regulation of c-myc accompanies terminal differentiation and
permanent withdrawal from the cell cycle (Canelles, M. et al, 1997; Griep, A and Westphal,
H., 1988; Holt, J. e al, 1988; Prochownik, E. et al, 1988). My results demonstrate that
quinidine inhibits Myc protein and mRNA levels in human breast cancer cells, probably by
regulating the activity of c-myc promoter. Therefore, we tested whether quinidine also
induces differentiation in these cells. The effects of quinidine on Ki-67 antigen expression
and accumulation of the cytoplasmic lipid droplets have been tested.

4.1. Quinidine decreases the percentage of the MCF-7 cells expressing the Ki-67
antigen
Ki-67 is a nuclear protein found in cells that are actively engaged in the cell cycle (van
Dierendonck, et al, 1989). The turnover rate of Ki-67 protein is less than 1 hour (Bruno and
Darzynkeiwicz, 1992); therefore, its absence from cells is an indication that cells have exited
the cell cycle and entered G0 or non-proliferative state that is associated with the cellular
differentiation.
To test the effects of quinidine on the expression of Ki-67 protein, MCF-7 cells were
replica plated at the density of 2 x 105/35 mm2 tissue culture dish in 3 ml of DMEM/5%FBS
medium +/- 90 µM quinidine. Twelve, 18, 24, 30, 48, and 72 hours later cells were fixed and
stained for Ki-67 immunoreactivity as detailed in the Materials and Methods. Figure 20
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shows a representative picture of the control and quinidine-treated MCF-7 cells after
immunohistochemical staining of Ki-67 antigen (brown color) and counter-staining with
Mayer's hematoxylin (blue color). Brown cells (Ki-67-positive) represent cell population in
G1, S, G2, and M phase of the cell cycle. Blue cells (Ki-67-negative) represent the
population of cells in G0 or non-proliferative state. The Ki-67-negative and positive cells
were scored using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD).
A minimum of 500 cells were counted per experimental condition. The results are shown in
Figure 21. The quinidine-treated cells showed a significant increase in Ki-67 negative cells
between 48 and 72 hours, compared to the control cells. These data suggest that quinidinetreated MCF-7 cells begin to accumulate in the G0 state after 24 hours of treatment.
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Figure 20. Ki-67 immunohistochemical staining of MCF-7 cells.
Control or 90 µM quinidine-treated MCF-7 cells were grown for 48 hours on the glass cover
slips and assayed for Ki-67 immunoreactivity. Brown staining indicates Ki-67 positive or
cycling cells. Blue staining indicates Ki-67 negative or G0 cells.
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Figure 21. Increase in G0 cell population in MCF-7 cells treated with quinidine.
Control or 90µM quinidine-treated MCF-7 cells were grown on the glass cover slips. At the
indicated times, cells were stained for Ki-67 immunoreactivity, and Ki-67 positive and
negative cells were counted. Between 200 and 700 cells were counted per experimental
condition. The bars represent the percentage of Ki-67 negative cells in control (solid bars)
and quinidine-treated cells (hatched bars). The data are mean +/- SEM of two to five
experiments.
∗ Significantly different from control values (p<0.05).
Wang, S., et al, 1998.
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4.2. Quinidine causes accumulation of cytoplasmic lipid droplets in MCF-7 cells.
Lipid droplets are found in the cytoplasm of normal mammary epithelium (Jing, Y. et al,
1996), and cytoplasmic lipid droplet accumulation occurs in a variety of differentiating cell
systems. Induction of differentiation in human breast cancer cell lines by retinoic acid
(Bacus. S. et al, 1990), the vitamin D analog, 1-α- hydroxyvitamin D5 (Mehta, R. et al,
2000), and oncostatin M (Douglas, A. et al, 1998) is accompanied by the accumulation of
cytoplasmic lipid droplets.
To determine whether quinidine treatment induces the accumulation of cytoplasmic lipid
droplets, the MCF-7 cells were replica plated at the density of 2 x 105/35 mm2 tissue culture
dish in 3 ml of DMEM/5%FBS medium +/- 90 µM quinidine. Seventy-two, 96, and 120
hours later cells were fixed and the Oil-Red O staining of the cells was performed as
described in the Material and Methods. Figure 22 shows a representative picture of the
control and quinidine-treated MCF-7 cells after the Oil-Red O staining and counter-staining
with Mayer's hematoxylin to visualize the cytoplasmic lipid droplets (red color) and the cell
nuclei (blue color), respectively. The Oil-Red O staining of the normal human mammary
epithelial cells (HMEC), performed in an identical manner as for MCF-7 cells is also shown
in the Figure 21. This picture demonstrates the morphological similarities between the
quinidine-treated MCF-7 cells and untreated HMEC, implying that quinidine-treated tumor
cells acquire a more differentiated phenotype. MCF-7 cells were scored as positive or
negative for the presence of cytoplasmic lipid droplets using Image-Pro Plus software (Media
Cybernetics, Silver Spring, MD). A minimum of 500 cells was counted per experimental
condition. The results are shown in Figure 23. Quinidine caused a significant increase in lipid
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droplets-positive MCF-7 cells at 70, 96, and 120 hours of treatment, compared to the control
cells.
In summary, the presented data show that quinidine treatment after 24 hours caused
accumulation of MCF-7 cells in G0 state with the induction of the cytoplasmic lipid droplets
after 48 hours. Since in general these changes are observed during cellular differentiation, we
conclude, that quinidine induces a more differentiated phenotype in MCF-7 human breast
cancer cells.
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Figure 22. Oil Red O staining of the MCF-7 and HMEC.
Control or 90 µM quinidine-treated cells were grown on glass cover slips. At the indicated
times cells were stained with the Oil Red O stain (red dots in the cytoplasm) and
counterstained with the Mayer’s hematoxylin (blue nuclei).

102

Figure 23. Quinidine causes accumulation of cytoplasmic lipid droplets in the MCF-7
cells.
Control or 90 µM quinidine-treated MCF-7 cells were grown on the glass cover slips. At the
indicated times cells were stained with Oil Red O to monitor accumulation of cytoplasmic
lipid droplets. Lipid droplet positive and negative cells were counted. The bars represent the
percentage of lipid droplet positive cells in control (solid bars) and quinidine-treated (hatched
bars) cells. At least 500 cells were counted per experimental condition. Data shown in the
histogram are the mean +/- S.D. of n = 3 experiments for 70 hours and results from single
experiments for 96 and 120 hours.
∗ Significantly different from control values (p<0.05).
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4.3. Quinidine induces more differentiated phenotype in other breast cancer cell lines.
The objective of this experiment was to test if quinidine induces more differentiated
phenotype in other breast tumor cell lines. MCF-7, T47D, MDA-231, and MDA-435 cells
were replica-plated at the densities of 0.8-3 x 105/35 mm2 tissue culture dish in 3 ml of
DMEM/5%FBS +/- 90 µM quinidine or 10 µM retinoic acid for 96 hours. The retinoic acid
has been shown to induce differentiation in human breast cancer cells (Bacus. S. et al, 1990).
Therefore, it was used as a positive control in this experiment. The Nile Red fluorescent
stain, instead of the Oil Red O, was used to monitor lipid droplet formation in response to
quinidine. The cells were counterstained with fluorescein-conjugated antibodies to phalloidin
that bind actin filaments to assay for the changes in the actin cytoskeleton. The results are
shown in Figure 24. Lipid droplet accumulation was weak or absent in the control cell lines
and increased by retinoic acid and quinidine. Lipid droplets accumulation was more marked
in all four cell lines treated with quinidine than with retinoic acid.
These data demonstrate that induction of a more differentiated phenotype is a general
response of human mammary tumor cells to quinidine.
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Figure 24. Accumulation of cytoplasmic lipid droplets in mammary tumor cell lines in
response to quinidine.
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MCF-7, T47D, MDA-231, and MDA-435 cells were grown on glass cover slips in medium
containing 0.01% ethanol (control), 10 µM retinoic acid, or 90 µM quinidine. After 96 hours,
cells were fixed and stained with the Nile Red and fluorescein-phalloidin to identify lipid
droplets (orange color) and actin filaments (green color), respectively. Images were obtained
by confocal microscopy.
Zhou, Q, et al, 2000.
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4.4. Quinidine inhibits proliferation in human breast tumor cell lines
The data presented above suggest that quinidine induces differentiation in breast tumor
cell lines. In general, the process of cellular differentiation is associated with an exit from the
cell cycle and cessation of proliferation. Therefore, we next tested if quinidine also inhibits
the growth in human mammary tumor cells. The effects of quinidine on cell growth was
assayed by two different methods. In the first method breast cancer (MCF-7, MDA-231,
MDA-435) and normal (HMEC, MCF10A) cells were replica-plated at the density of 1-1.5
x105/35 mm2 dish in the DMEM/5% FBS (tumor cells) of MEGM (normal cells) medium +/90 µM quinidine. Cell numbers were counted using a hemocytometer as described in the
Materials and Methods. In the second method, cells were plated in a 96-well dishes at the
following densities, depending upon the relative growth rates of the cell lines: HMEC (2000),
MCF10A (1000), MCF-7 (1000), MDA-231 (500), T47D (1500). Cell growth was monitored
using the MTS enzymatic assay as detailed in the Materials and Methods. The results are
shown in Figure 25. Quinidine suppressed growth in all breast tumor cell lines, while having
no effect in normal breast epithelial cells.
The data presented above suggest that quinidine induces more differentiated phenotype
and selectively inhibits cell growth in four different tumor, but not in normal breast epithelial
cell lines.
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Figure 25. Quinidine selectively inhibits growth in human breast tumor, but not in
normal cell lines.
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MCF-7, MDA-231, T47D, MCF-7ras tumor cells, and normal HMEC and MCF10A cells
were replica-plated in 96-well plates for the MTS assay, or in 35 mm2 dishes for the cell
count assay in control (open symbols) or 90 µM quinidine-containing medium (solid
symbols). For the MTS assay (circles), results are the average of quadruplicates in one
experiment. For the cells count assay (squares), the results represent the mean and SEM of
three independent experiments for the MCF-7, T47D, and MDA-231 cell lines in duplicate
dishes (MCF-7 and T47D), or single dishes (MDA-231) for each experiment. MCF-7ras and
MCF10A data are the mean +/- range of two experiments performed in duplicate dishes.
HMEC cell count data are from one experiment performed in single dishes.
Zhou, Q., et al, 2000.
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4.5. c-myc antisense oligonucleotides mimic the effects of quinidine on lipid droplets
formation in the MCF-7 cells
The objective of this experiment was to test if suppression of Myc is sufficient to
induce a more differentiated phenotype in breast tumor cells similar to quinidine. In fact,
blocking of Myc activity using antisense oligonucleotides was shown to induce
differentiation in several cell lines (Griep, A and Westphal, H., 1988; Holt, J. e al, 1988).
MCF-7 cells were plated at the density of 2.2 x 105/35 mm2 tissue culture dish on glass cover
slips in DMEM/5%FBS. Cells were allowed to attach to the cover slips and then the medium
was exchanged to DMEM/2%FBS +/- 9 µM c-myc antisense oligonucleotides or +/- c-myc
sense oligonucleotides (negative control). Ninety-six hours later cells were fixed and Oil Red
O staining was performed as described in the Materials and Methods. The results are shown
in Figure 26. MCF-7 cells treated with c-myc antisense oligonucleotides showed
accumulation

of

cytoplasmic

lipid

droplets,

whereas

control

and

c-myc

sense

oligonucleotides-treated cells were predominantly lipid droplet-negative. These results
suggest that specific down-regulation of the Myc activity is sufficient to induce lipid droplet
formation in MCF-7 cells. Thus, it is conceivable, that inhibition of c-myc by quinidine is
responsible for the morphological changes associated with more differentiated phenotype
observed in quinidine-treated breast tumor cells. The presented results, as well as the data
from other laboratories, suggest a critical role for Myc in regulation of cellular growth and
differentiation in breast tumor cells. Therefore, it is important to understand the precise
molecular mechanisms regulating c-myc gene expression by quinidine, which may reveal
new pharmacological targets for breast cancer therapy.
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Figure 26. c-myc antisense oligonucleotides cause accumulation of cytoplasmic lipids in
MCF-7 cells.
MCF-7 cells were plated on glass cover slips and treated with nothing (control), 9 µM c-myc
antisense oligonucleotides (mycAS), or 9 µM c-myc sense oligonucleotides (mycS). 96 hours
later cells were stained with Oil Red O (red color) and counterstained with Mayer’s
hematoxylin (blue color) to visualize cytoplasmic lipid droplets and cell nuclei, respectively.
The results are representative of n= 2 experiments.
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IV. DISCUSSION

Previous studies indicate that quinidine causes G1/G0 cell cycle arrest and inhibition of
proliferation in MCF-7 human breast cancer cell line (Woodfork, K. et al, 1995). The goal of
studies presented here was to further understand the mechanisms underlying cell cycle arrest
and inhibition of growth by quinidine. The regulation of c-myc gene by quinidine in human
tumor and normal breast epithelial cell lines were studied.
C-myc is one of the most common oncogene aberrations in breast cancers (Deming, S. et
al, 1999; Garcia, I. et al, 1989; Escot, C. et al, 1986). The abnormal expression of c-myc was
reported in 32% of breast cancers (Liu, E. et al, 1989), suggesting its important role in
genesis and/or progression of breast cancer. Hence, understanding the mechanisms of c-myc
gene regulation is important and may lead to the discovery of new targets for breast cancer
therapy. In vivo studies with c-myc antisense oligonucleotides showed a significant increase
in cancer-free survival of Eµ-transgenic mice compared to the animals treated with
scrambled (negative control) oligonucleotieds (Akhtar, S. and Agrawal, S., 1997). In
addition, mice with human melanoma xenografts showed a significant decrease in tumor size
after systemic administration of c-myc antisense oligonucleotides (Leonetti, C. et al, 2001).
My results demonstrate significant suppression of Myc by quinidine in four different human
breast cancer cell lines growing in tissue culture (Figure 8). A large body of evidence
established an important role of c-myc in cellular differentiation. Studies in different cell
lines had shown that down-regulation of c-myc by antisense oligonucleotides or expression of
dominant negative c-myc gene accompanies terminal differentiation and permanent
withdrawal from the cell cycle (Ebinuma, H. et al, 1999; Canelles, M. et al, 1997; Griep, A.
and Westphal, H., 1988; Holt, J. et al, 1988; Prochownik, E. et al, 1988). Conversely,
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independent studies showed that ecotpic c-Myc expression from a transfected gene is
sufficient to block the induction of differentiation in MEL, 3T3-L1 preadipocyte, F9, PC12
neuronal, and U-937 monoblastic cell lines (Coppola, J.A., and Cole, M.D., 1986;
Dmitrovsky, E. et al, 1986; Freytag, S., 1988; Larsson, L., et al, 1988; Maruyama, K. et al,
1987, Onclercq, R. et al, 1989; Prochownik, E. and Kukowska, J., 1986). In consistence with
these data, my results demonstrate that suppression of Myc by quinidine was associated with
inhibition of growth and induction of a more differentiated (less malignant) phenotype in
four different breast tumor cell lines (Figures 24 and 25).
The induction of differentiation (differentiation therapy) with a vitamin A derivative, alltrans retinoic acid (ATRA) has been a major advance and become the first choice drug in the
treatment of acute promyelocytic leukemia (APL) (Tobita, T. et al, 1997; McBurney, M. et
al, 1993). The major principle behind the differentiation therapy is a pharmacologically
induced conversion of poorly differentiated cancer cells back to the original differentiated or
non-proliferative state. Since normal cells are already differentiated, ideally, they should not
be affected by differentiation-inducing agents, leading to the less side effects compared to
traditional cytotoxic chemotherapy. The successful treatment of APL with all-trans retinoic
acid had led to attempts to apply the same principle for the treatment of other cancers.
Unfortunately, differentiation therapy for solid cancers, such as breast cancer, generally, has
been proven to be ineffective. Therefore, induction of a more differentiated phenotype in
breast cancer cells by quinidine is a promising finding, suggesting a potential role for
quinidine-like compounds in the therapy of breast cancer. In addition, differentiationinducing agents, such as retinoids, have been shown to be very effective in chemopreventive
studies in breast cancer, cervical cancer, head and neck cancer, and lung cancer (Whelan, P.,

113

1999). Chemoprevention is a relatively new branch of oncology, which aims to use chemical
agents to reduce the incidence of malignant diseases in humans by suppressing
carcinogenesis in premalignant lesions. In analogy to retinoids, quinidine-like compounds
may also be effective as breast cancer chemopreventive agents. A better understanding of
factors and mechanisms regulating differentiation (such as down-regulation of the c-myc), as
well as their disruption in carcinogenesis would reveal new possibilities to design novel
therapeutic approaches for chemopreventive and differentiation therapy of solid tumors. The
results from my experiments indicate that quinidine suppresses the activity of c-myc
promoter over the same range of concentrations that suppress levels of c-myc mRNA and
protein (Figure 14). Myc protein, mRNA levels, and promoter activity were suppressed by
68% (Figure 9), 78% (Figure 11), and 60-70% (Figure 16A) respectively by 90µM quinidine.
The changes in c-myc mRNA and protein levels in response to quinidine may therefore be
attributed to its effects on c-myc promoter. Furthermore, a 168 bp region (from –100 to +68
in respect to P1) of the c-myc promoter was identified as a putative quinidine response region
(QRR) (Figures 15 and 16). This region contains two important cis-elements: the TGF β1
control element (TCE) and region from -60 to -37 that contains Sp1/Sp3 binding site
(Nishikura, K., 1986, see Table 3). The first element is involved in inhibition of c-myc P1
transcription initiation in response to TGF β1 (Pietenpol, J. et al, 1991), whereas the presence
of intact second element is essential for P1 transcription (Nishikura, K., 1986). Quinidine had
no effects on the levels of Sp1 or Sp3 proteins in MCF-7 cells (Figure 17). These results
indicate that suppression of c-myc promoter by quinidine is not mediated by the changes in
Sp1/Sp3 protein levels. However, it does not exclude the possibility of Sp1/Sp3 involvement
in regulation of c-myc promoter by quinidine, since binding of these proteins to the GC-rich
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region of QRR but not their levels could be responsive to quinidine. This issue can be
resolved by electrophoretic mobility shift assay, that directly examines protein/DNA
interactions in the promoter region of interest. In addition, my results suggest that regulation
of c-myc and subsequently cell growth by quinidine and TGFβ1 is mediated by different
mechanisms in breast cancer cell lines. It is also possible that suppression of the c-myc
promoter in response to quinidine is mediated by the region within QRR that has not been
described yet. To identify this potential new element, the fine mapping of QRR should be
done by making small promoter deletions using polymerase chain reaction (PCR) and
targeted single-stranded DNA primers. Determination of QRE may lead to the identification
of transcription factors that mediate suppression of c-myc promoter activity by quinidine.
This in turn may reveal the signaling pathways that are involved in the regulation of c-myc
gene and are targeted by quinidine.
Alternative mechanism, by which quinidine can alter the expression of c-myc gene is via
changing the acetylation of histones associated with c-myc promoter or transcription factors
that bind to it. The chromatin structure and consequently the transcriptional activity of genes
can be modulated by two families of proteins, via changes in the acetylation status of
histones (Grunstein, M., 1997; Davie, J. and Chadee, D., 1998). Deacetylation of histones by
histone deacetylases (HDACs) is, in general, associated with more condensed or
transcriptionally inactive chromatin. In contrast, the hyperacetylation of histones by histone
acetylases (HATs) has been linked to the transciptionally active chromatin (Kornberg, R. and
Lorch, Y., 1999; Kouzarides T., 1999; Grunstein, M., 1997). A large body of evidence
demonstrated, that agents that inhibit HDAC enzymatic activity, such as trichostatin A
(TSA), superoylanilide hydroxamic acid (SAHA), trapoxin, and phenyl butyrate induce
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differentiation in a number of cell lines (Marks, P. et al, 2000; Medina, V. et al, 1997;
Richon, V. et al, 1998; Sambucetti, L., 1999). The results from our laboratory showed that
quinidine causes rapid degradation of HDAC-1, followed by histone hyperacetylation in
MCF-7 cells (Zhou, Q. et al, 2000). Several studies, which used Raji cells (B cell line) stably
transfected with episomal c-myc gene within self-replicating Epstein-Barr virus-derived
vector, showed that mRNA transcription from both c-myc promoters, P1 and P2, is induced
by two HDAC inhibitors, sodium butirate (Albert, T. et al, 2001) and tricostatin A (Madisen,
L. et al, 1998). Therefore, suppression of c-myc promoter by quinidine is unlikely to be a
result of quinidine-induced histone hyperacetylation. On the other hand, degradation of
HDAC-1 by quinidine can alter the acetylation and subsequently DNA binding or
transactivating activities of transcription factors that regulate c-myc promoter activity. In fact,
the activities of several transcription factors have been reported to depend on their
acetylation status (Gu, W. and Roeder, R., 1997; Munshi, N. et al, 1998; Waltzer, L. and
Bienz M. et al, 1998).
One of the major problems of current chemotherapeutic drugs for breast cancer treatment
is their lack of selectivity for tumor tissue and associated with it toxicity in normal tissues.
Importantly, quinidine had minimal effects on Myc levels or proliferation in normal breast
epithelial cell lines (Figures 10 and 25). The difference in responses of tumor and normal
cells to quinidine could be due to the lack of quinidine’s target in normal cells or its
overexpression in tumor cells. For example, if changes in membrane potential in response to
quinidine are involved and ultimately lead to the suppression of Myc, then the levels of
expression of quinidine-sensitive potassium channels could be different in normal and cancer
cells. In fact, the unique linear hyperpolarized current, which is inhibited by quinidine in
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MCF-7 cells, is overexpressed in their Ha-ras transformed counterpart (Klimatcheva, E. and
Wonderlin, W., 1999). The differential regulation of Myc in normal versus tumor cells could
also be attributed to the differences in c-myc promoter sequence in these cells.
In the studies presented here, as well as in the previous studies the maximal responses to
quinidine were achieved at 90 µM concentration. The IC50 values of quinidine for growth
inhibition, G0/G1 arrest, and suppression of Myc protein levels were 37.15 (Woodfork, K.
dissertation, 1993), 24 +/-14 (Wang, S., 1998), and 27.3 +/- 13 µM (Figure 9), respectively.
These values are above the therapeutic concentrations of quinidine as antiarrhythmic drug,
which range from 2 to 6 µg/ml (5.3 to 15.8 µM). Additionally, 6 µg/ml (15.8 µM), 9 µg/ml
(24 µM), and 14 µg/ml (37 µM) concentrations of quinidine caused side effects in 10, 30,
and 50 % of patients, respectively (Goodman and Gilman’s, VII edition, 1985). The IC50
values of quinidine for G0/G1 (24 µM) arrest and suppression of Myc (27µM) are close to
the dose (24 µM) that causes toxic effects in only 30 % of patients. To minimize the toxic
effects, the lower doses of quinidine can be used in combination with other differentiationinducing agents, such as retinoids. In fact, most of the chemotherapeutic regiments employ
combination or polychemotherapy, consisting of the use of two or more compounds to
achieve maximum kill of tumor cells with minimal toxicity.
In summary, the studies presented here demonstrate a significant suppression of Myc
levels by quinidine, which followed by inhibition of proliferation and induction of a more
differentiated phenotype in four different human breast cancer cell lines growing in tissue
culture. In contrast, quinidine had minimal effects on Myc protein levels and proliferation in
normal breast epithelial cells. Differentiation-inducing agents, such as retinoids, have been
successfully used for the treatment of acute promyelocytic leukemia, but not solid cancers. In
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addition, retinoids, have been shown to be very effective in chemopreventive studies in
breast cancer, cervical cancer, head and neck cancer, and lung cancer. Furthermore, in vitro
and in vivo studies with c-myc antisense oligonucleotieds have shown promising results in
treatment of several cancers. Therefore, suppression of Myc and induction of a more
differentiated phenotype in breast cancer cells by quinidine is a promising finding,
suggesting a potential role for quinidine-like compounds in chemopreventive and
differentiation therapies of breast cancer.
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